



Europäisches
Patentamt
European
Patent Office
Office européen
des brevets



(11)

EP 4 019 523 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(43) Date of publication:
29.06.2022 Bulletin 2022/26

(51) International Patent Classification (IPC):
C07F 5/02^(2006.01) C07D 241/02^(2006.01)

(21) Application number: **20855543.3**

(52) Cooperative Patent Classification (CPC):
C07D 241/02; C07F 5/02; Y02P 20/55

(22) Date of filing: **18.08.2020**

(86) International application number:
PCT/CN2020/109818

(87) International publication number:
WO 2021/032088 (25.02.2021 Gazette 2021/08)

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **19.08.2019 CN 201910764541
12.08.2020 CN 202010806347**

(71) Applicant: **Shanghai Forefront Pharma Co., Ltd.
Shanghai 201203 (CN)**


(72) Inventors:

- RONG, Bin**
Shanghai 201203 (CN)
- ZHAO, Lizhi**
Shanghai 201203 (CN)
- LI, Wei**
Shanghai 201203 (CN)
- REN, Yi**
Shanghai 201203 (CN)


(74) Representative: **Rondano, Davide et al
Società Italiana Brevetti S.p.A.
Via Carducci 8
20123 Milano (IT)**

(54) METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND

(57) The invention relates to a preparation method of L-erythro biopterin compound. Among them, the L-erythro biopterin compound is of a structure as shown in formula (I), and the L-erythro biopterin compound represented by formula (I) is mainly obtained by a dihydroxylation reaction of the compound with a structure as shown in formula (II) or formula (III);



The preparation method of L-erythro biopterin compound is of high production efficiency, low cost, is environment-friendly, and suitable for industrial production.



PLAT791 ALERT 4 G Model has Chirality at N1
And 3 other PLAT791 Alerts

(Chiral SPGR)

S Verify

PLAT791 ALERT 4 G Model has Chirality at C2
PLAT791 ALERT 4 G Model has Chirality at C6
PLAT791 ALERT 4 G Model has Chirality at C7

(Chiral SPGR)

S Verify

(Chiral SPGR)

R Verify

(Chiral SPGR)

S Verify

Fig 1

Description


[0001] This application claims the priority to Chinese patent application No. 2019107645414 filed with the China National Intellectual Property Administration on August 19, 2019, entitled "Preparation Method of L-Erythro Biopterin Compound" and Chinese patent application No. 2020108063470 filed with the China National Intellectual Property Administration on August 12, 2020, entitled "Intermediates for Preparing L-Erythro Biopterin Compound and Preparation Method Thereof", the entire contents of which are incorporated in this application by reference.

Technical field


[0002] The present invention relates to the technical field of drug preparation, and particularly to the preparation method of L-erythro biopterin compound.

Background of the invention

[0003] The L-erythro biopterin compound represented by formula (I) is an important intermediate for most drugs, especially for the sapropterin drugs. For example, (R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(3H)-pteridinone (BH4) represented by formula (Ib) is an essential coenzyme in hydroxylation reactions and oxygenases *in vivo* and is the most important coenzyme of nitric oxide synthase (NOS). Its hydrochloride (i.e., sapropterin dihydrochloride, represented by structural formula (Ic)) has been approved by many countries for the treatment of phenylketonuria.




[0004] At present, sapropterin dihydrochloride is mainly synthesized by hydrogenation/reduction of the compound represented by formula (Ia).



[0005] Therefore, research and development is currently focused on the safe and efficient method to produce L-erythro biopterin compound represented by formula (Ia).

[0006] At present, there are many reports on the synthesis of L-erythro biopterin compound. For example, Andrews et al. (J. Chem. Soc. 1969, 928) reported the preparation of biopterin by condensation of 5-deoxy-L-arabinose with 2-amino-4-chloro-3-nitro-6-hydroxypyrimidine. However, both the optical purity and chemical purity are insufficient and scale-up production is unachievable.

[0007] Welustock J. (US3505329), and Taylor E.C. (J. Am. Chem. Soc. 1979, 98, 2301) reported a method with higher optical selectivity, as shown in the following route:




L-rhamnose is used as the raw material, which reacts with ethanethiol to generate thioacetal, which is oxidized to sulfone, and then one carbon is removed by alkali treatment to obtain 5-deoxy-L-arabinose (D). Then, 5-deoxy-L-arabinose reacts with 2,4,5-triamino-6-hydroxypyrimidine (TAP) to generate L-erythro biopterin. After subsequent improvements (Helv chim acta 1985:1639), the method has become the current industrialized route. In the method, 5-deoxy-L-arabinose (D) is first treated with phenylhydrazine, and then treated with acetic anhydride to convert to corresponding acetylphenylhydrazone (G), followed by cyclization with TAP. The obtained product is not separated but immediately oxidized to obtain the acetylated L-erythro biopterin, which is further deprotected to obtain L-erythro biopterin.


[0008] However, this industrial route has following significant deficiencies: 1) The synthesis of the critical intermediate 5-deoxy-L-arabinose involves condensation of L-rhamnose with ethanethiol with a strong foul smell to obtain acetal, which is complicated in operations and causes serious pollution, and thus is no longer used in industry at present; 2) The intermediate 5-deoxy-L-arabinose itself is unstable, cannot be stored for a long time, and thus must be prepared immediately before use; 3) The intermediates in the steps for preparing 5-deoxy-L-arabinose are oily substances and unstable, so all the intermediates from C to L-erythro biopterin cannot be purified, which makes the process difficult to control the quality and carry out GMP production; 4) The process for preparing L-erythro-biopterin by condensation of 5-deoxy-L-arabinose derivative with 2,4,5-triamino-6-hydroxypyrimidine (TAP) shows poor selectivity, numerous impurities and low yield; and (5) The generated L-erythro-biopterin is extremely difficult to be purified due to its extremely poor solubility in common solvents, and the poor quality directly and adversely affects the quality of sapropterin hydrochloride subsequently prepared by hydrogenation.

[0009] Based on the current technologies, the improvement in process of L-erythro-biopterin compound worldwide mostly focus on the preparation of 5-deoxy-L-arabinose, especially using other reagents instead of thiol to reduce odor and pollution. There is no significant progress in the condensation of 5-deoxy-L-arabinose derivative with TAP, and the raw materials are expensive, the route is long, and the yield is low, resulting in high production costs and low safety performance, which cannot meet the production needs in modern pharmaceutical industry. Therefore, it is urgent to develop a preparation method of L-erythro biopterin compound, which is of high efficiency, low cost, is environment-friendly, and suitable for industrial production.

Summary of the invention


[0010] Based on this situation, the present invention provides a method for preparing L-erythro biopterin compound, which is of high production efficiency, low cost, is environment-friendly, and suitable for industrial production. Intermediate represented by structural formula (IVa-1), (IVa-2), (IVa-3), (IVa-4), (IVa) or (IVa'):





[0011] In which,

10



15

represents the structure generated by the reaction of dihydroxyl, the first reagent and the second reagent;

20



represents the structure generated by the reaction of dihydroxyl and the first reagent;

[0012] The first reagent is boric acid ester or boric acid;

[0013] The second reagent is chiral amino alcohol;

25

W is NH_x , and X is 0, 1 or 2;

R_1 is a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

30

R_2 and R_3 are independently a hydrogen atom or an amino-protecting group; and R_2 and R_3 together with the nitrogen atom connected to R_2 and R_3 can form a cyclic lactim group;

R_4 is $-\text{COOR}_5$, $-\text{CONR}_6$ or $-\text{CN}$;

R_5 and R_6 are independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

35

Z is a hydrogen atom or a leaving group;


Y is O or absent.

[0014] The method for preparing the intermediate mentioned above includes the following steps:

40

Mix the compound to be separated (a mixture of compounds represented by formulas (IVa) and (Iva')), the first reagent, the second reagent and the aprotic solvent, and heat to reflux. After the reaction is completed, crystallize to obtain the intermediate represented by structural formula (IVa-1) or (IVa-2);

45




50

[0015] The intermediates mentioned above can be used to prepare L-erythro biopterin compound.

[0016] It is a method for preparing L-erythro biopterin compound. The L-erythro biopterin compound is represented by structural formula (I), and prepared by dihydroxylation of the compound represented by formula (II) or formula (III);

55



[0017] In which,

Y is O or absent:

Z is a hydrogen atom or a leaving group:

R_1 is a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

R_2 and R_3 are independently a hydrogen atom or an amino-protecting group; and R_2 and R_3 together with the nitrogen atom connected to R_2 and R_3 can form a cyclic lactim group;

R_4 is $-COOR_5$, $-CONR_6$ or $-CN$;

R_5 and R_6 are independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

R_7 is $-OH$ or $-NH_2$. L-erythro biopterin compound prepared by the above-mentioned method for preparing L-erythro biopterin compound.

[0018] A method for preparing sapropterin drugs includes the following steps:

Prepare the L-erythro biopterin compound represented by formula (I) by the above-mentioned method for preparing L-erythro biopterin compound;

allow the L-erythro biopterin compound represented by formula (I) to undergo hydrogenation/reduction.

[0019] The L-erythro biopterin compound can be used to prepare drugs for treating phenylketonuria and hyperphenylalaninemia.

[0020] The method for preparing L-erythro biopterin compound can be used to prepare drugs for treating phenylketonuria and hyperphenylalaninemia.

Brief description of the drawings

[0021] Figure 1 shows the single crystal structure of compound **3a**.

Detailed description of the invention

[0022] For the purpose of understanding the present invention, a more comprehensive description of the present invention is given below, and preferred embodiments of the present invention are given. However, the present invention can be embodied in a variety of different forms and should not be limited to the embodiments described herein. On the contrary, these embodiments are provided for the purpose of more thorough and comprehensive understanding of the public disclosures of the present invention.

[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by the technicians in the field of the present invention. The terminology used in the patent specification of the present invention is given for the purpose of describing specific embodiments only, and is not intended to limit the present invention. The term "and/or" used herein includes any and all combinations of one or more of the relevant listed items.

Explanation of terms

[0024] In the present invention, unless otherwise stated in the present invention, the meaning denoted by the same symbol should be understood as having the same meaning. In addition, unless otherwise stated, each term (including substituent abbreviations, reagent name abbreviations, etc.) in the present invention should be understood as having the ordinary meaning in the field.

[0025] In the present invention, a leaving group should be understood as the ordinary meaning in the field, referring to an atom or a functional group that can be removed from a large molecule in a chemical reaction. It is apprehensible that, unless otherwise stated, in reaction steps involving compounds containing a leaving group, including the steps of introducing and removing a leaving group, the introduction and removal of a leaving group can be done by methods commonly used in the field according to the specific type of the leaving group used, which will not be specifically limited herein.

[0026] In the present invention, the amino-protecting group should be understood as the ordinary meaning in the field, referring to the protecting group of amino group. It is apprehensible that, unless otherwise stated, in reaction steps involving compounds containing a protecting group, including the steps of introducing and removing a protecting group, the introduction and removal of a protecting group can be done by methods commonly used in the field according to the specific type of the protecting group used, which will not be specifically limited herein.

[0027] In the present invention, "substituted or unsubstituted" means that the defined group can be substituted or unsubstituted. When a defined group is substituted, it should be understood as being substituted by any one group acceptable in the field, including but not limited to: alkyl with 1 to 20 carbon atoms, cycloalkyl with 3 to 20 ring atoms, heterocycl with 3 to 20 ring atoms, aryl with 5 to 20 ring atoms, heteroaryl with 5 to 20 ring atoms, silicyl, carbonyl, alkoxy carbonyl, aryloxy carbonyl, carbamoyl, haloformyl, formyl, -NRR', cyano, isocyano, isocyanate group, thiocyanate group, isothiocyanate group, hydroxyl, trifluoromethyl, nitro, or halogen. The groups can be further substituted with acceptable substituents in the field. It is apprehensible that each of R and R' in -NRR' is independently substituted by an acceptable group in the field, including but not limited to, H, alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 8 ring atoms, heterocycl with 3 to 8 ring atoms, aryl with 5 to 20 ring atoms, or heteroaryl with 5 to 10 ring atoms. The alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 8 ring atoms, heterocycl with 3 to 8 ring atoms, aryl with 5 to 20 ring atoms, or heteroaryl with 5 to 10 ring atoms can be further substituted by any one or more of the following groups: C₁₋₆ alkyl, cycloalkyl with 3 to 8 ring atoms, heterocycl with 3 to 8 ring atoms, halogen, hydroxyl, nitro or amino.

[0028] In the present invention, a site not labeled with a stereoconfiguration should be understood to include a variety of stereoconfigurations that can exist stably.

[0029] "Alkyl" refers to a saturated aliphatic hydrocarbyl, including straight and branched chain groups. C_{1-C₆} alkyl refers to an alkyl of 1 to 6 carbon atoms. Non-limiting embodiments include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, and 2,3-dimethylbutyl. C_{1-C₄} alkyl refers to an alkyl of 1 to 4 carbon atoms. In one embodiment, C_{1-C₄} alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and sec-butyl. The alkyl can be substituted or unsubstituted, and when substituted, the substituent can be substituted at any available connection point.

[0030] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbyl substituent. The 3-8 membered cycloalkyl refers to a cycloalkyl containing 3 to 8 carbon atoms. In one embodiment, the 3-8 membered monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, and cyclooctyl, etc. Polycyclic cycloalkyl includes spiro, fused and bridged cycloalkyl. The cycloalkyl can be substituted with one or more substituents.

[0031] "Heterocycl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbyl substituent, in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)_m (in which m is an integer from 0 to 2), preferably nitrogen or oxygen heteroatoms, excluding the ring portion of -O-O-, -O-S- or -S-S-, and the remaining ring atoms are carbon. The 4-10 membered heterocycl refers to a ring of 4 to 10 ring atoms, in which 1 to 3 members are heteroatoms. The preferred heterocycl ring contains from 5 to 6 ring atoms, in which 1 to 2 members are heteroatoms. In one embodiment, monocyclic heterocycl groups include dihydrofuranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl or homopiperazinyl, etc.

[0032] "Aryl" refers to an all-carbon monocyclic or fused polycyclic group having a conjugated π -electron system (i.e., a ring sharing adjacent pairs of carbon atoms), preferably groups having from 6 to 10 members, more preferably phenyl and naphthyl, most preferably phenyl. The aryl ring can be fused to a heteroaryl, heterocycl or cycloalkyl ring, and the aryl can be substituted or unsubstituted.


[0033] "Heteroaryl" refers to a heteroatom-containing aryl, in which heteroatoms include oxygen, sulfur and nitrogen. The heteroaryl is preferably a 5- or 6-membered group, such as a furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocycl or cycloalkyl

ring, and the ring connected to the parent structure is the heteroaryl ring. The heteroaryl can be substituted or unsubstituted.

[0034] In the present invention, the substituent "amino group" includes primary, secondary, or tertiary amino groups. Specifically, the amino group includes $-\text{NR}_{16}\text{R}_{17}$, in which R_{16} and R_{17} are hydrogen atom or any optional group, e.g., H, substituted or unsubstituted straight chain alkyl, substituted or unsubstituted branched alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, etc.

[0035] "Silicily" refers to $-\text{Si}(\text{alkyl})_3$, and the three alkyl groups connected to silicon can be the same or different from each other.

[0036] The cyclic lactim group has a structure



15

, the number of ring atoms contained in ring A is not specifically limited, it can be a 5-membered ring, 6-membered ring, etc., e.g., glutarimide, succinimide, etc.

[0037] In the present invention, the abbreviations are given in the table below:

20

Abbreviations	English name
Me	Methyl
TBS	t-butyldimethylsilyl
Boc	t-butyloxycarbonyl
Cbz	Benzylloxycarbonyl
Ac	Acetyl
Ts	p-toluenesulfonyl
Ms	Mesyl (methanesulfonyl)
Bz	Benzoyl
Bn	Benzyl
PMB	p-methoxybenzyl
schiff base	Schiff base
dppf	1,1'-bis(diphenylphosphino)ferrocene
Xantphos	4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
Xphos	2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
DBU	1,8-diazabicyclo[5.4. 0] undec-7-ene
NMP	1-methyl-2-pyrrolidinone
THF	Tetrahydrofuran
2-MeTHF	2-methyltetrahydrofuran
ACN	Acetonitrile
MIBK	Methyl isobutyl ketone
ee	Enantiomeric excess
er	Enantiomer ratio
dr	Diastereomer ratio

25

30

35



40

45

50

55

[0038] One embodiment of the present invention provides intermediate represented by structural formula (IVa-1), (IVa-2), (IVa-3), (IVa-4), (IVa) or (IVa'):



[0039] In which,



represents the structure generated by the reaction of dihydroxyl, the first reagent and the second reagent;

25



30 represents the structure generated by the reaction of dihydroxyl and the first reagent;

[0040] The first reagent is boric acid ester or boric acid;

The second reagent is chiral amino alcohol, chiral amino acid, chiral amino acid ester or chiral diol; W is O or NH_x , and X is 0, 1 or 2;

35

R_1 is a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

R_2 and R_3 are independently a hydrogen atom, or an amino-protecting group; among them, the amino-protecting group includes but is not limited to: -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or schiff base; and R_2 and R_3 together with the nitrogen atom connected to R_2 and R_3 can form a cyclic lactim group;

40

R_4 is $-\text{COOR}_5$, $-\text{CONR}_6$ (i.e., CONHR_6) or $-\text{CN}$;

Z is a hydrogen atom or a leaving group; among them, the leaving group includes but is not limited to: halogen (e.g., Cl, Br, I), OSO_nR_9 , OCOR_{10} or $\text{OPO}_2\text{R}_{11}$. R_9 , R_{10} , or R_{11} is independently selected from: $-\text{CF}_3$, alkyl, phenyl, or alkyl-substituted phenyl (e.g., tolyl). n is 0, 1 or 2, and the silyl group can be a silyl group, etc.

Y is O or absent.

45

[0041] In one embodiment, R_1 is selected from C_{1-6} alkyl, 3-8 membered cycloalkyl, 3-10 membered aryl, 3-10 membered heteroaryl, TMS, TBS, or $-\text{CH}_2\text{X}$; X is a leaving group. In one embodiment, R_1 is selected from C_{1-6} alkyl, cyclopropyl, phenyl, pyridyl, TMS, TBS, or $-\text{CH}_2\text{X}$; X is a leaving group. In one embodiment, R_1 is methyl.

50

[0042] R_5 and R_6 are independently a hydrogen atom, or a substituted or unsubstituted C_{1-20} alkyl. In which, C_{1-20} alkyl can be further substituted by C_{1-6} alkyl, 3-8 membered cycloalkyl, 3-10 membered aryl, 3-10 membered heteroaryl, hydroxyl, halogen, amino, cyano, or C_{1-4} alkoxy.

[0043] Further, R_5 and R_6 are independently a hydrogen atom, or a substituted or unsubstituted C_{1-6} alkyl. C_{1-6} alkyl can be further substituted by C_{1-4} alkyl, 3-8 membered cycloalkyl, 3-10 membered aryl, 3-10 membered heteroaryl, hydroxyl, halogen, amino, cyano, or C_{1-4} alkoxy.

55

[0044] In one embodiment, R_4 is $-\text{CN}$.

[0045] In one embodiment, Y is absent, Z is a hydrogen atom, R_4 is a cyano, and R_1 is a methyl.

[0046] It is apprehensible that the R_8 group in




5 is determined according to the selected boric acid ester. Further, R_8 is a substituted or unsubstituted alkyl group; furthermore, R_8 is a substituted or unsubstituted C_{1-10} alkyl group, or a substituted or unsubstituted C_{3-10} cycloalkyl group; furthermore, R_8 is a substituted or unsubstituted C_{1-8} alkyl group or a substituted or unsubstituted C_{3-8} cycloalkyl group; and furthermore, R_8 is a substituted or unsubstituted C_{1-6} alkyl group or C_{3-6} cycloalkyl group;

10 [0047] It is apprehensible that the boric acid ester in the present invention can be any acceptable boric acid ester reagent in this field; in one embodiment, the boric acid ester is selected from: trimethyl borate, triethyl borate, triisopropyl borate or isopropoxyboronic acid pinacol ester; in addition, the chiral amino alcohol can be any acceptable chiral amino alcohol in the field; in one embodiment, the chiral amino alcohol is selected from: L-phenylglycinol, L-prolinol, L-phenylalaninol, (S)-(-)- α,α -diphenylprolinol, quinine or cinchoni, so as to obtain the product of the desired configuration with higher ee value and yield. In the present invention, the chiral amino acid can be any acceptable chiral amino acid in the field; in one embodiment, the chiral amino acid is selected from the following chiral amino acids: L-phenylalanine, L-alanine, L-proline, L-leucine, L-valine, L-phenylglycine, etc. In the present invention, the chiral amino acid ester can be any acceptable chiral amino acid ester in the field; in one embodiment, the chiral amino acid ester is selected from: L-phenylalanine ester, L-alanine ester, L-proline ester, L-leucine ester, L-valine ester, and L-phenylglycine ester, etc., and the selected ester can be alkyl ester or aryl ester; the chiral diol can be any acceptable chiral diol in the field; in one embodiment, the chiral diol is a diol containing 1,2-diol or 1,4-diol chiral structure; further, the chiral diol is selected from: chiral BINOL, chiral hydrogenated benzoin, (trans)-9,10-dihydroxy-9,10-dihydrophenanthrene, or (cis)-9,10-dihydroxy-9,10-dihydrophenanthrene, etc.

15 [0048] Further, the second reagent is preferably a chiral amino alcohol for better separation effect.

20 [0049] In one embodiment,


25



30


has the structure

35



; further,


40



45

has the following structure:

50



55

[0050] In which at least one of the carbon atom connected to R_{20} and R_{21} and the carbon atom connected to R_{22} and R_{23} is a chiral carbon;

R_{20} , R_{21} , R_{22} and R_{23} are independently selected from: H, substituted or unsubstituted C_{1-6} alkyl, substituted or

unsubstituted phenyl, substituted or unsubstituted naphthyl, or substituted or unsubstituted quinolyl;
 5 R₂₄ and R₂₅ are independently selected from: H, substituted or unsubstituted C₁₋₆ alkyl, or substituted or unsubstituted phenyl;
 R₂₃ and R₂₄ can connect with each other to form a ring structure;
 R₂₃, R₂₄ and R₂₅ can connect with each other to form a bridged ring structure.


[0051] It is apprehensible that the "ring structure" in the present invention includes monocyclic ring (e.g., aromatic ring, heterocyclic ring), spiro ring, bridged ring, etc.

[0052] In one embodiment, R₂₀, R₂₁, R₂₂ and R₂₃ are independently selected from: H, phenyl, C₁₋₆ alkyl or alkoxy substituted quinolyl;


[0053] In one embodiment, R₂₄ and R₂₅ are independently selected from: H, C₁₋₆ alkyl, or phenyl;

[0054] In one embodiment, R₂₃ and R₂₄ can connect with each other to form a five-membered nitrogen-containing heterocyclic ring;

[0055] In one embodiment, R₂₃, R₂₄, and R₂₅ can connect with each other to form a structure




[0056] In one embodiment,



[0057] The present invention also provides the method for preparing the intermediates mentioned above, which includes the following steps:

Mix the compound to be separated (a mixture of compounds represented by formulas (IVa) and (IVa')), the first reagent, the second reagent and the aprotic solvent, and heat to reflux. After the reaction is completed, crystallize to obtain the intermediate represented by structural formula (IVa-1) or (IVa-2);



[0058] It is apprehensible that the reaction process of the reaction mentioned above should not be understood as limitations to the present invention. The reaction process can be as follows: First, the compound to be separated reacts with the first reagent to generate a mixture of compounds represented by structural formulas (IVa-3) and (IVa-4). Then, the mixture of compounds represented by structural formulas (IVa-3) and (IVa-4) reacts with the second reagent to obtain the intermediate represented by structural formula (IVa-1) or (IVa-2). Among them, the mixture of compounds represented by structural formulas (IVa-3) and (IVa-4) can be separated or unseparated, which should be understood as within the protection scope of the present invention.

[0059] Further, the reaction mentioned above includes the following steps:

50 S001: The compound to be separated is dissolved in an aprotic solvent;

Further, the aprotic solvent in step S001 is selected from one or more of the following solvents: tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), acetonitrile (ACN), toluene, benzene, 1,4-dioxane (1,4-diox), and acetone, so as to increase the differences in solubility of the intermediates with different configurations, and precipitate the intermediate of desired configuration (formula (IVa-1)), further reduce the difficulty of separation, meanwhile, increase the yield and ee value of the product. Furthermore, the aprotic solvent is acetonitrile. Further, add 1-100 mL of aprotic solvent per g of the compound to be separated. Furthermore, add 20-80 mL of aprotic solvent per g of the compound to be separated. Furthermore, add 30-60 mL of aprotic solvent per g of the compound to be


separated.

[0060] S002: Add the first reagent and the second reagent, heat to reflux and react for a period of time predetermined; Through adding the first reagent and the second reagent, a new chiral center is introduced into the diastereomer, and thus a pair of diastereomers is obtained. Finally, separation can be achieved through crystallization. In addition, the compound represented by formula (IVa-1) obtained by this method is a critical intermediate for the preparation of L-erythro biotin compound, and is precipitated as a solid in most conventional aprotic solvents, which can significantly reduce the difficulty of separation and increase the ee value of the product. For example, when boric acid ester and chiral amino alcohol are used, the specific reaction mechanism is as follows:

10

15

20



25

[0061] Further, the first reagent is boric acid ester or boric acid.

[0062] Further, the second reagent is chiral amino alcohol, chiral amino acid, chiral amino acid ester or chiral diol. Furthermore, the second reagent is chiral amino alcohol.

[0063] The first reagent and the second reagent are described as above, and will not be repeated here.

30

[0064] Furthermore, the boric acid ester is triisopropyl borate, the chiral amino alcohol is L-prolinol, and the solvent is acetonitrile.

[0065] Further, the molar ratio of the compound to be separated to the boric acid ester is less than or equal to 1. Further, the molar ratio of the first reagent to the second reagent is 1:(1.0-1.3). Further, the molar ratio of the first reagent to the second reagent is 1:1.

35

[0066] It is apprehensible that the order of addition of the reagents in step S002 is not specifically limited, and should not be understood as a limitation to the present invention, e.g., add the first reagent first, then add the second reagent, or add the first reagent and the second reagent simultaneously; in addition, the reaction time of step S002 is not specifically limited, which is adjusted according to the type of reagent used, and should not be understood as a limitation to the present invention;

40

[0067] Further, in step S002, add the first reagent first and react for 25-50 min, then add the second reagent and react for 8-24 h.

[0068] S003: Crystallize to obtain the intermediate represented by structural formula (IVa-1) or (IVa-2);

45

[0069] It is apprehensible that crystallization can be carried out by existing methods, and the temperature for solid-liquid separation in the crystallization process can be adjusted according to the solvent selected specifically, which should not be understood as a limitation to the present invention. In one embodiment, crystallization is carried out as follows: After the reaction is completed, cool the reaction liquid. A solid precipitate is formed. Separate the solid and liquid phases. The product of desired conformation is either the solid- or liquid-phase product.

55

[0070] The method for preparing the intermediate represented by structural formula (IVa-1) or (IVa-2) has the following advantages:

50

Since the solubility of the intermediate represented by structural formula (IVa-1) or (IVa-2) is different in aprotic solvents, only crystallization is required to make one of the intermediates represented by structural formulas (IVa-1) and (IVa-2) dissolve in the solvent and the other precipitate out. The products with different configurations can be separated by simple solid-liquid separation, which effectively reduces the difficulty of separation and is particularly suitable for industrial production;

The reaction conditions of the above-mentioned separation reagent set consisting of the first reagent and the second reagent are mild, and the requirements for the quality and purity of the substrate is loose. The ee value, dr value and purity of the product obtained after separation are extremely high. The separation can be realized even if the purity of the compound to be separated is 70%. Meanwhile, the purity of the obtained product can be increased to

99%. One-pot separation and purification is effectively realized;

The intermediate represented by structural formula (IVa-1) or (IVa-2) obtained by the above-mentioned method can be directly used for production in the next reaction step without separation. The ee and dr values can be further increased after the next synthesis step. Experiments showed that when a product with a ee value of 88% (IVa-1/IVa-2 = 94/6) is used for the next reaction step, the ee of the final product can also be increased to greater than 99.9%, with chiral purity comparable to that of natural chiral introduction;

The obtained intermediate represented by structural formula (IVa-1) or (IVa-2) is solid, structurally stable, and easy for quality control, production, storage and transportation.


[0071] The present invention also relates to a chiral separation reagent set comprising the first reagent and the second reagent. The first reagent is boric acid ester or boric acid, and the second reagent is chiral amino alcohol, chiral amino acid, chiral amino acid ester or chiral diol. The reagents are described as above, and will not be repeated here.

[0072] The present invention also relates to a chiral separation reagent set consisting of chiral amino alcohol and boric acid ester.

[0073] Further, the chiral separation reagent set mentioned above consists of boric acid ester and L-proline. Further, the chiral separation reagent set mentioned above consists of boric acid ester and L-phenylglycinol. Further, the chiral separation reagent set mentioned above consists of boric acid ester and (S)-(-)- α,α -diphenylprolinol. Further, the chiral separation reagent set mentioned above consists of boric acid ester and quinine. Further, the chiral separation reagent set mentioned above consists of boric acid ester and cinchonni.

[0074] The present invention also relates to the application of the chiral separation reagent set mentioned above in the preparation of L- erythro biopterin compound.

[0075] In one embodiment of the present invention, the L-erythro biopterin compound is mainly prepared using the compound represented by structural formula (II) or (III) through dihydroxylation. Among them, the L-erythro biopterin compound is represented by structural formula (I):



[0076] In which, Y is O or absent. In one embodiment, Y is absent.

[0077] Z is a hydrogen atom or a leaving group; among them, the leaving group includes but is not limited to: halogen (e.g., Cl, Br, I), OSO_nR₉, OCOR₁₀ or OPO₂R₁₁. R₉, R₁₀, or R₁₁ is independently selected from: -CF₃, alkyl, phenyl, or alkyl-substituted phenyl (e.g., tolyl). n is 0, 1 or 2, and the silicily group can be a silyl group, etc. R₁ is a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

[0078] R₂ and R₃ are independently a hydrogen atom, or an amino-protecting group; among them, the amino-protecting group includes but is not limited to: -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or schiff base.

[0079] R₂ and R₃ together with the nitrogen atom connected to R₂ and R₃ can form a cyclic lactim group, e.g., glutarimide, and succinimide. It is apprehensible that R₂ and R₃ together with the nitrogen atom to which they are connected do not necessarily form a cyclic lactim group, which is selected as necessary.


[0080] R₄ is -COOR₅, -CONR₆, or -CN. In one embodiment, R₄ is -CN.

[0081] R₅ and R₆ are independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

[0082] In the above-mentioned preparation method of L-erythro biopterin compound, the alkene compound represented by formula (II) or (III) is innovatively used as the raw material, and the dihydroxy of desired configuration is constructed through a dihydroxylation reaction, which effectively avoids the use of intermediates such as 5-deoxy-L-arabinose (D),

and thus avoids the use of ethanethiol with a strong foul smell, and effectively reduces environmental pollution, and is environment-friendly. In addition, the reaction conditions for dihydroxylation of alkenes are relatively mild, the operation is convenient, the yield is relatively high, and the raw material represented by structural formula (II) or (III) is readily available, which can greatly shorten the reaction route, further improve the efficiency, reduce the production cost, and is suitable for industrial production.

[0083] It is apprehensible that, while performing the reactions described in the present invention, common reactions in the field (e.g., oxidation reaction, reduction reaction) are used to convert raw materials into the desired compound (e.g., compound represented by formula (II) or (III)), regardless of whether the desired compound (e.g., compound represented by formula (II) or (III)) is separated or directly used in subsequent reaction, it should be understood as within the protection scope of the present invention. For example: For the cyclization reaction of



(R₄ is -CHO), an oxidizing agent is added before or while the cyclization reaction is undergoing (in the one-pot reaction, oxidation and cyclization occurs simultaneously) to convert the aldehyde group to carboxylic acid or carboxylic ester, followed by the cyclization reaction. It should be understood that it is equivalent to the technical scheme in which R₄ is carboxylic acid or carboxylic ester, and regardless of whether or not performing separation to the compound containing carboxylic acid or carboxylic ester, it should be understood as within the protection scope of the present invention.

[0084] In one embodiment, R₁ is selected from C₁₋₆ alkyl, 3-8 membered cycloalkyl, 3-10 membered aryl, 3-10 membered heteroaryl, TMS, TBS, or -CH₂X; X is a leaving group. In one embodiment, R₁ is selected from C₁₋₆ alkyl, cyclopropyl, phenyl, pyridyl, TMS, TBS, or -CH₂X, and X is a leaving group. In one embodiment, R₁ is methyl.

[0085] R₅ and R₆ are independently a hydrogen atom, or a substituted or unsubstituted C₁₋₂₀ alkyl. In which, C₁₋₂₀ alkyl can be further substituted by C₁₋₆ alkyl, 3-8 membered cycloalkyl, 3-10 membered aryl, 3-10 membered heteroaryl, hydroxyl, halogen, amino, cyano, or C₁₋₄ alkoxy.

[0086] R₇ is -OH or -NH₂. When R₇ is -NH₂, a compound with R₇ as -OH can be obtained by hydrolysis under alkaline conditions.

[0087] It is apprehensible that the term "dihydroxylation" should be understood as the ordinary meaning in the field, referring to a reaction at the double bond site of an alkene (e.g.,



R₁ in formula (II) or (III)) to generate an o-dihydroxy compound. The dihydroxylation methods include, but are not limited to, Sharpless asymmetric dihydroxylation reaction, basic KMnO₄ dihydroxylation reaction, Fe-catalyzed dihydroxylation or asymmetric epoxidation followed by hydrolysis and ring opening. The Sharpless asymmetric dihydroxylation is preferable. The inventor has found in the research process that if the compound represented by formula (II) or formula (III) is used as the reactant, and the Sharpless asymmetric dihydroxylation reaction is employed, the product of desired configuration can be obtained in a higher yield, the difficulty of separation is greatly reduced and the efficiency of production is improved.

[0088] It should be noted that the alkene group (



R₁) in formula (II) or (III) can be a cis or trans structure.


[0089] It is apprehensible that in the reaction, the compound represented by formula (II) or (III) can be a pure substance, i.e., a compound represented by formula (II) or (III) containing only the cis structure, or a compound represented by formula (II) or (III) containing only the trans structure, or a mixture, i.e., a mixture of the cis and trans structures, which will not be specifically limited herein (preferably a compound represented by the cis structural formula (II)). The mixture can be separated by chiral separation after reaction. The chiral separation method is not specifically limited, and can be an existing separation method. The compound represented by formula (II) undergoes dihydroxylation reaction, followed by cyclization to obtain the L-erythro biopterin compound represented by formula (I). Among them, the cyclization methods can be existing methods, such as those in Journal of Organic Chemistry 1987, 52(18), 3997-4000 and Journal of Organic Chemistry 1988, 53 (1), 35-38.

1. Preparation of L-erythro biopterin compound from compound represented by formula (II)

1.1 Preparation of L-erythro biopterin compound from cis-alkene

5 [0090] When the alkene in the compound represented by formula (II) is of a cis structure, the steps for preparing the L-erythro biopterin compound represented by formula (I) from the compound represented by formula (II) are as follows: S111: The compound represented by formula (IIa) is subjected to a dihydroxylation reaction to obtain the compound represented by formula (IVa).

10



15

Formula (IIa)

Formula (IVa)

20 [0091] Among them, the dihydroxylation reaction in step S111 includes but is not limited to: Sharpless asymmetric dihydroxylation reaction, basic KMnO_4 dihydroxylation reaction, Fe-catalyzed dihydroxylation reaction or asymmetric epoxidation followed by hydrolysis and ring opening. Sharpless asymmetric dihydroxylation reaction is preferred.

25

(1) When the Sharpless asymmetric dihydroxylation reaction is used for the reaction, step S111 can include the following steps: Mix the compound represented by formula (IIa), the oxidizing agent, the dihydroxylation reagent, the base and the ligand for reaction. After the reaction is completed, quench the reaction and separate. The reaction is preferably carried out at 0-25°C. After the reaction is completed, the reaction can be quenched with sodium sulfite. After quenching, the insoluble matter is filtered, the organic phase is collected, and chiral separation is performed to the organic phase to obtain a single chiral compound represented by formula (IVa) (R,S).

30

[0092] Further, the dihydroxylation reagent is selected from one or more of the following reagents: OsO_4 , K_2OsO_4 , OsO_4 hydrate and K_2OsO_4 hydrate; the oxidizing agent is selected from $\text{K}_3[\text{Fe}(\text{CN})_6]$ or NMO and both; the base is selected from one or more of the following reagents: potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, NaOH , KOH , LiOH , NH_4OH , t-BuONa , t-BuOK , t-BuOLi , triethylamine, diisopropylethylamine, DBU, pyridine and p-dimethylaminopyridine; the ligand is selected from one or more of the following reagents: $(\text{DHQ})_2\text{PHAL}$, $(\text{DHQD})_2\text{PHAL}$, DHQ-IND and DHQD-IND; the solvent can be one or more of acetone, methanol, ethanol, 1,4-dioxane, tert-butanol, and THF.

35

[0093] In addition, in the above-mentioned step S111, an osmate ester hydrolyzing agent can also be added, and the osmate ester hydrolyzing agent includes but is not limited to methanesulfonamide.

40

[0094] In addition, it is preferred that the amount ratio of the compound represented by formula (IIa) to the solvent is 1 g:(10-100 mL); the molar ratio of the compound represented by formula (IIa) to the oxidizing agent is 1 :(0.1%-20%); the molar ratio of the compound represented by formula (IIa) to the base is 1:(1-10); the molar ratio of the compound represented by formula (IIa) to methanesulfonamide is 1:(1-10).

45

[0095] (2) When the basic KMnO_4 dihydroxylation reaction is used for the reaction, step S111 can include the following steps: Mix the compound represented by formula (IIa), the dihydroxylation reagent, the base and the solvent for reaction. After the reaction is completed, chiral separation is performed.

50

[0096] Further, the dihydroxylation reagent is KMnO_4 ; the base can be one or more of potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, NaOH , KOH , LiOH , NH_4OH , t-BuONa , t-BuOK , t-BuOLi , cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine and p-dimethylaminopyridine; the solvent is one or more of acetone, methanol, ethanol, 1,4-dioxane, tert-butanol and THF.

55

[0097] (3) When the Fe-catalyzed dihydroxylation reaction is used for the reaction, step S111 can include the following steps: Mix the compound represented by formula (IIa), the dihydroxylation reagent, the catalyst, and the solvent for reaction. After the reaction is completed, chiral separation is performed.

[0098] Further, the dihydroxylation reagent is hydrogen peroxide; the catalyst is one or more of $\text{Fe}(\text{ClO}_4)_2$, $\text{Fe}(\text{OTf})_2$, FeCl_2 , and FeBr_2 ; the solvent can be one or more of acetone, methanol, ethanol, 1,4-dioxane, tert-butanol and THF.

[0099] (4) When the epoxidation reaction is used for the reaction, step S111 can include the following steps: The compound represented by formula (II) reacts with an epoxidation reagent to obtain an epoxidized intermediate, then the ring is opened with acid or base, and perform chiral separation to obtain the desired dihydroxylation product.

55

[0100] The preferred epoxidation reagent is one or more of m-CPBA, DMDO, and salen-Mn(III)/ NaOCl ; the solvent can be one or more of methylene chloride, tetrahydrofuran, 1,4-dioxane, and tert-butanol. The acid used for ring opening can be dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, etc., and the base used can be KHCO_3 .

K₂CO₃, KOH, etc.


[0101] It is apprehensible that "chiral separation" after the above-mentioned dihydroxylation reaction can be performed by using a chiral column or chemical separation. The chiral separation reagent set is preferred for the separation of the compound to be separated. The chiral separation reagent set includes the first reagent and the second reagent. The first reagent is boric acid ester or boric acid; the second reagent is chiral amino alcohol, chiral amino acid, chiral amino acid ester or chiral diol. The reagents are described as above and will not be repeated here;

[0102] Further, step S111 includes the following steps:

S1111: The compound represented by formula (IIa) is subjected to dihydroxylation reaction to obtain the compound to be separated, which is composed of the compounds represented by formula (IVa) and formula (IVa');

10

15



20

25

[0103] Further, the dihydroxylation reaction is described as above and will not be repeated here.

[0104] S1112: The compounds to be separated are separated using a chiral separation reagent set to obtain the compound represented by formula (IVa-1);

30

S112: Through a cyclization reaction with

35



and/or the salt of

40



, the L-erythro biopterin compound represented by formula (I) is obtained;

Specifically, L-erythro biopterin compound represented by formula (I) can be prepared according to the following steps S112a and S112b;

45

S112a: The compound represented by formula (IVa) undergoes a cyclization reaction with

50



and/or the salt of

55



, by which the L-erythro biopterin compound represented by formula (I) is obtained;

in step S112 refers to a salt that contains



and can be an acceptable salt in this field, such as a hydrochloride. It is apprehensible that the



and/or the salt of



can contain acceptable protecting groups in this field, and it should be understood that all of them are within the protection scope of the present invention.

[0108] Step S112a is essentially the same as S112b except that the compound represented by formula (IVa) is used instead of the compound represented by formula (IVa-1) in step S112b. Now, it is further explained by taking step S112b as an example:

[01091] Further, step S112b includes the following steps:


25 S1121: Cyclization step: Mix the compound represented by formula (IVa-1).



and/or the salt of



, base and solvent, and heat to 50-100°C for reaction. After the reaction is completed, cool. A solid substance is precipitated. Filter and obtain the solid substance (i.e., the compound represented by formula (I-1)).



[01111] The definitions of Y, Z, R₁, R₂, R₃ and R₄ are described as above and will not be repeated here. R₇ is -OH or -NH₂.

[0112] Furthermore, the above-mentioned cyclization step includes the following steps: Add Na to MeOH, stir until the reaction is completed. Then add



and/or the salt of



5 , and stir at room temperature for a predetermined time (preferably 3-10 min) under the protection of N_2 . Then, filter the insoluble matter in the system, add the compound represented by formula (IVa-1), and heat to reflux. After the reaction is completed, cool to room temperature and stir for 40 min-80 min. Filter to obtain the solid substance precipitated.

10 [0113] In the above-mentioned cyclization step, the solvent is a protic solvent, which is preferably an alcohol solvent, including but not limited to one or more of methanol, ethanol and isopropanol. The base can be one or more of sodium ethoxide, sodium methoxide, t-BuONa, t-BuOK, and t-BuOLi; it is preferably a strong base, such as sodium methoxide. The molar ratio of the compound represented by formula (IVa-1) to

15 and/or the salt of

20 is 1 :(1-3); the molar ratio of the compound represented by formula (IVa-1) to the base is 1 :(2-5); the ratio of the compound represented by formula (IVa-1) to the solvent is 1 g:(5-100 mL). In the above-mentioned cyclization step, R_4 is used as

25 the raw material of $COOR_5$, $-CONR_6$ or $-CN$, and the

30 and/or the salt of

35 is used innovatively for the cyclization reaction to form the desired ring, which is initially applied to the synthesis of

40 biopterin compounds. Compared with the traditional method, it has obvious advantages: High atom availability, high conversion rate, and clean reaction; by-products are soluble in the reaction solvent, while the product is insoluble and easy to purify. This process only needs to filter the product and simply wash, then high-purity product (98%-99%) can be obtained. The cost of


45 and/or the salt of

50 is relatively low, which can further reduce the production cost. However,



is used as a raw material in the traditional cyclization process, and it is necessary to accurately adjust the pH value of the reaction system and accurately control the temperature to hydrolyze the acetyl group, so as to prevent the breaking of side chain at position 6 during hydrolysis. It is difficult to operate and not suitable for industrial production.

[0114] S1122: Hydrolysis step: Add the solid substance (i.e., the compound represented by formula (1-1)) obtained in the cyclization step to an alkaline solution for reaction. After the reaction is completed, add acid, and adjust the pH to 5-6. Crystals are precipitated. Filter and dry to obtain the L-erythro biopterin compound represented by formula (1).



15 [0115] The definition of R_1 is described as above and will not be repeated here. R_7 is -OH or -NH₂.

[0116] Furthermore, the step of hydrolysis includes the following steps: Suspend the compound represented by formula (1-1) in an alkaline solution, heat to 50°C-100°C, and stir for 2 h-5 h; cool to room temperature, and then add acid to adjust the pH to 5-6. There are crystals precipitated. Filter and dry to obtain the L-erythro biopterin compound represented by formula (I).

20 [0117] Among them, the alkaline solution can be an inorganic alkaline solution, such as sodium hydroxide solution and potassium hydroxide solution, and a sodium hydroxide solution with a mass percentage of 5%-40% is preferred. Preferably, the molar ratio of the compound represented by formula (1-1) to the base is 1 :(5-20), more preferably 1:(5-10). The acid can be an organic acid or an inorganic acid, such as formic acid, hydrochloric acid, sulfuric acid, and hydrobromic acid, and formic acid is preferred.

25 [0118] It is apprehensible that when R_4 is -COOR₅ or -CONR₆, the hydrolysis step can be omitted.

[0119] It is apprehensible that when the compound represented by formula (IVa-1) is processed to obtain the compound represented by formula (IVa), the steps for the compound represented by formula (IVa) reacting with




and/or the salt of




40 are basically the same as those in the method mentioned above. It is only necessary to replace the compound represented by formula (IVa) with the compound represented by formula (IVa-1), which will not be repeated here.

1.2 Preparation of L-erythro biopterin compound from trans-alkene

45 [0120] When the alkene in the compound represented by formula (II) is of a trans structure, the steps for preparing the compound represented by formula (I) from the compound represented by formula (II) are as follows:
S121: The compound represented by formula (IIb) is subjected to a dihydroxylation reaction to obtain the compound represented by formula (IVb-1) and/or formula (IVb-2).




[0121] The dihydroxylation reaction in step S121 is the same as that in step S111, and will not be repeated here. S122: The compound represented by formula (Ivb-1) and/or the formula (Ivb-2) is subjected to an acetylation reaction to obtain the compound represented by formula (IIb-1) and/or formula (IIb-2).



[0122] Among them, the acetylation reaction in step S122 can include the following steps:


Dissolve the compound represented by formula (Ivb-1) and/or the compound represented by formula (Ivb-2), acetylation reagent and p-toluenesulfonamide (PTSA) in the solvent, stir for 20 min-50 min, then add water and continue stirring. After the reaction is completed, the compound represented by formula (VIIb-1) and/or formula (VIIb-2) can be obtained by separation. Among them, the acetylation reagent includes but is not limited to one or more of acetic anhydride, trimethyl orthoacetate, and acetyl chloride; the solvent can be one or more of acetonitrile, THF, dioxane, DCM, MTBE, etc.

[0123] S123: The compound represented by formula (VIIb-1) and/or formula (VIIb-2) is subjected to Mitsunobu reaction to obtain the compound represented by formula (VIIb-3) and/or formula (VIIb-4).



[0124] Specifically, it can include the following steps:

[0125] Dissolve the compound represented by formula (VIIb-1) and/or formula (VIIb-2), nucleophile




5 , PPh_3 or Bu_3P , diisopropyl azodicarboxylate (DIAD) or diacetate azodicarboxylate (DEAD) in a solvent for reaction.

[0126] After the reaction is completed, separate to obtain the desired product. Specific reagent combinations include but are not limited to: DEAD/ PPh_3 , DIAD/ PPh_3 , DEAD/ $\text{n-Bu}_3\text{P}$, DIAD/ $\text{n-Bu}_3\text{P}$, etc.

[0127] In which R_{10} is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; preferably R_{10} is substituted or unsubstituted aryl. When aryl is further substituted, the substituent is selected from C_{1-6} alkyl or C_{1-6} alkoxy. More preferably, R_{10} is

15



20




represents the connection site.

[0128] R_{11} is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; preferably R_{11} is H or C_{1-6} alkyl.

[0129] In one embodiment,

30



(naproxen).

[0130] S124: The compound represented by formula (VIIb-3) and/or formula (VIIb-4) undergoes a cyclization reaction with

35



40 and/or the salt of




45

(preferably guanidine salt), followed by hydrolysis to obtain the L-erythro biopterin compound represented by formula (I).

50

55



[0131] Step S124 is the same as step S112, and will not be repeated here. The definitions of Y, Z, R₁, R₂, R₃, R₄ and R₁₀ are described as above, and will not be repeated here. E is halogen, C₁₋₄ alkoxy, C₁₋₄ alkylthio or -NH₂. Further, E is methoxy, chlorine, methylthio or -NH₂;

[0132] When the alkene in the compound represented by formula (II) is of a cis structure, through a dihydroxylation reaction and a cyclization reaction, the product of desired configuration can be obtained in two steps with high yield, which can greatly shorten the reaction route, improve the production efficiency, and reduce the production cost. When the alkene in the compound represented by formula (II) is of a trans structure, first, the dihydroxylation reaction is used to construct dihydroxy and form two chiral centers, and then a highly selective mono-acetylation reaction of vicinal diols is used innovatively to achieve acetylation of one of the hydroxyl groups, and the Mitsunobu reaction is used to achieve the chiral inversion of the other hydroxyl group, so as to obtain the intermediate with desired configuration, and then cyclize to obtain the desired product, which greatly expand the range for selecting raw materials, and then relative inexpensive raw materials can be selected. In addition, the acetylation reaction, Mitsunobu reaction and other steps are of high yields, and the by-product of monoacetylation and the by-product that did not flip-over in the Mitsunobu reaction can also be recovered to be raw materials by simple hydrolysis and be reused, which ensures the economy of the entire route and meets the requirements of industrial production.

2. Preparation of L-erythro biopterin compound from compound represented by formula (III)

[0133] It is apprehensible that the compound represented by formula (III) can be a commercially available raw material, or can be prepared from the compound represented by formula (II) through a cyclization reaction. For example, the compound represented by formula (II) can be used for cyclization with




and/or the salt of



2.1 Preparation of L-erythro biopterin compound from cis-alkene


[0134] Further, when the alkene in the compound represented by formula (III) is of a cis structure, the steps for preparing the L-erythro biopterin compound represented by formula (I) from the compound represented by formula (III) are as follows:

[0135] S211: The compound represented by formula (III) is subjected to a dihydroxylation reaction to obtain the compound represented by formula (1-1).




[0136] The reaction reagents and reaction conditions of the dihydroxylation reaction in step S211 are as described in step S111, and will not be repeated here.

[0137] It is apprehensible that the chiral separation reagent set mentioned above can also be used for separation in step S211. The separation method and the chiral separation reagent set are described as above. It is only necessary to replace the compound to be separated in step S111 with the compound to be separated (mixture of



represented by the formula (III) and generated after the substrate dihydroxylation reaction. It is not repeated here, and it should be understood that all of them are within the protection scope of the present invention.

[0138] S212: The compound represented by formula (I-1) is hydrolyzed under alkaline conditions (such as condition of sodium hydroxide) to obtain the L-erythro biopterin compound represented by formula (I).



30 [0139] Step S212 is the same as step S1122, and will not be repeated here.

2.2 Preparation of L-erythro biopterin compound from trans-alkene

[0140] When the alkene in the compound represented by formula (III) is of a trans structure, first, the compound represented by formula (III) undergoes a dihydroxylation reaction to form dihydroxy, followed by an acetylation reaction, and then by the Mitsunobu reaction to obtain the product of desired configuration. The specific method and steps are the same as those in S121 to S124, and will not be repeated here.

[0141] When the alkene in the compound represented by formula (III) is of a cis structure, through a dihydroxylation reaction, the product of the desired configuration can be obtained in a high yield, which can greatly shorten the reaction route, improve the production efficiency, and reduce the production cost. When the alkene in the compound represented by formula (III) is of a trans structure, first, the dihydroxylation reaction is used to construct dihydroxy and form two chiral centers, and then a highly selective mono-acetylation reaction of vicinal diols is used innovatively to achieve acetylation of one of the hydroxyl groups, and the Mitsunobu reaction is used to achieve the chiral inversion of the other hydroxyl group, and then hydrolyze to obtain the desired product, which greatly expand the range for selecting raw materials, and then relative inexpensive raw materials can be selected. In addition, the acetylation reaction, Mitsunobu reaction and other steps are of high yields, and the by-product of monoacetylation and the by-product that did not flip-over in the Mitsunobu reaction can also be recovered to be raw materials by simple hydrolysis and be reused, which ensures the economy of the entire route and meets the requirements of industrial production.

50 3. Preparation of compounds represented by formula (II) and formula (III)

[0142] It should be noted that the compound represented by formula (II) or formula (III) can be synthesized by existing methods, such as Heck reaction (see J. Chem. Soc., Chem. Commun. 1983, 15, 793-794), Grignard reaction (See Chemistry Letters 2014, 43(6), 922-924), alkyl lithium debromination and propenyl bromide reaction (see Chemistry-An Asian Journal 2012, 7(5), 1061-1068), Stille reaction (see J.Org.Chem.1990, 55, 3019), and Negishi coupling (see J. Chem. Soc., Chem. Commun. 1977, 683-684). It can also be a commercially available raw material, and it should be understood that all of the situations are within the protection scope of the present invention.


[0143] However, the applicant found in the research that: the cis-trans selection and region selection of the compound

represented by formula (II) or formula (III) prepared by the Heck reaction are poor; in the Grignard reaction, although the cis-trans can be controlled, it needs to prepare a less stable aryl group magnesium bromide, which is difficult to industrialize; in the alkyl lithium debromination and propenyl bromide reaction, the conditions are harsh, and the conversion rate is low; in the Stille reaction, alkenyl tin reagent is used to couple with the substrate, which needs to synthesize highly toxic organotin, and thus is not suitable for industrial production; in Negishi coupling, it needs to prepare unstable and flammable organozinc reagents, and the post-processing is complicated, which is not suitable for industrial production. It is preferably to synthesize according to the following method, so as to further improve the production efficiency and reduce the production cost.

10 3.1 Synthesis of compound represented by formula (II)

3.1.1 Synthesis of the compound represented by the cis structural formula (II)

15 [0144] When the alkene in the compound represented by formula (II) is a compound represented by the cis structural formula (IIa), the compound represented by formula (IIa) is obtained by catalytic hydrogenation of the compound represented by formula (V):



25 [0145] Specifically, it can include the following steps:


Mix the compound represented by formula (V), the catalyst and the solvent, and allow to react under a hydrogen atmosphere. After the reaction is completed, filter and concentrate to obtain the compound represented by the *cis* structural formula (IIa).

[0146] Among them, the catalyst can be selected from one or more of the following reagents: Lindlar catalyst, palladium/carbon, Raney nickel, platinum black and platinum dioxide. The solvent can be selected from one or more of the following reagents: tetrahydrofuran, 2-methyltetrahydrofuran, ethyl ether, methyl tert-butyl ether, methyl cyclopentyl ether, methanol, ethanol, isopropanol, acetonitrile and toluene.

[0147] Preferably, the ratio of amounts used of the compound represented by formula (V) to the solvent is 1 g:(1-100 mL), more preferably 1 g:(5-60 mL). The weight ratio of the compound represented by formula (V) to the catalyst is 1:(0.005-0.2), more preferably 1:(0.01-0.1). The pressure of hydrogen introduced is 0.1-10 MPa, more preferably 0.1-5 MPa; the reaction temperature is preferably 0-50°C.

[0148] Among them, the compound represented by formula (V) can be a commercially available raw material, or it can be synthesized by an existing method, and it is preferably synthesized by the following method:

40 S311: The compound represented by formula (V) is obtained by the Sonogashira reaction of the compound represented by formula (VI):



[0149] In which M is H or a leaving group, preferably M is a halogen, sulfonic ester, carboxylic ester or phosphoester. The leaving group includes but is not limited to: halogen (for example: Cl, Br, I), OSO_nR_9 , OCOR_{10} or $\text{OPO}_2\text{R}_{11}$. R_9 , R_{10} , or R_{11} is independently selected from: $-\text{CF}_3$, alkyl, phenyl, or alkyl-substituted phenyl (such as tolyl); n is 0, 1 or 2, and the silicil group can be a silyl group, etc. Among them, the sulfonic ester can be: methyl benzenesulfonic ester, methanesulfonic ester, trifluoromethanesulfonic ester, etc. More preferably, M is bromine. When using the above-mentioned reaction to prepare the compound represented by formula (V), the compound represented by formula (VI) which is widely available in the market can be used as the raw material, which significantly reduces the production cost, the reaction yield is high (> 95%), the reaction conditions at room temperature is mild, and the product can be obtained by conventional recrystallization.

[0150] Specifically, it can include the following steps:

S3111: Mix the compound represented by formula (VI), catalyst, ligand and solvent;

S3112: Add alkali and

5



for reaction. After the reaction is completed, quench the reaction and separate to obtain the compound represented by formula (V).

10

[0151] In the above-mentioned step S3111, it is preferable to dissolve at a temperature of 0-35° C, the catalyst is preferably a combination of copper catalyst and palladium catalyst, and the ligand is a phosphorus ligand. Among them, the copper catalyst can be one or more of cuprous chloride, cuprous bromide and cuprous iodide, and cuprous iodide is preferred. The palladium catalyst can be one or more of palladium chloride, acetic acid, $\text{PdCl}_2(\text{dppf})$, $\text{Pd}_2(\text{dba})_3$ and $\text{Pd}(\text{PPh}_3)_4$.

15

[0152] In addition, the solvent in the above-mentioned step S3111 can be one or more of tetrahydrofuran, 2-methyltetrahydrofuran, ethyl ether, methyl tert-butyl ether, methylcyclopentyl ether and acetonitrile, and 2-methyltetrahydrofuran is preferred. In step S3111, the base can be one or more of potassium carbonate, sodium carbonate, cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine and p-dimethylaminopyridine.

20

[0153] In addition, it is preferable that the ratio of amounts used of the compound represented by formula (VI) to the solvent is 1 g:(1-20 mL), preferably 1 g:(5-15 mL). The molar ratio of the compound represented by formula (VI) to the catalyst is 1:(1%-15%), preferably 1:(1%-10%). The molar ratio of the compound represented by formula (VI) to the ligand is 1:(2%-30%), preferably 1:(2-20%); the molar ratio of the compound represented by formula (VI) to the base is 1:(5-15).


25

3.1.2 Synthesis of compounds represented by trans structural formula (II)

30

[0154] When the alkene in the compound represented by formula (II) is a compound represented by the trans structural formula (IIb), the compound represented by formula (IIb) is obtained through a coupling reaction (such as: suzuki coupling reaction) of the compound represented by formula (VI);

35



45

[0155] In which M is H or a leaving group, preferably M is a halogen, sulfonic ester, carboxylic ester or phosphoester. The leaving group includes but is not limited to: halogen (for example: Cl, Br, I), OSO_nR_9 , OCOR_{10} or $\text{OPO}_2\text{R}_{11}$. R_9 , R_{10} , or R_{11} is independently selected from: $-\text{CF}_3$, alkyl, phenyl, or alkyl-substituted phenyl (such as tolyl); n is 0, 1 or 2, and the silicilyl group can be a silyl group, etc. Among them, the sulfonic ester can be: methyl benzenesulfonic ester, methanesulfonic ester, trifluoromethanesulfonic ester, etc. More preferably, M is bromine. Specifically, it can include the following steps:

50

Mix the compound represented by formula (VI), the trans-1-propenyl boronic acid reagent, the catalyst, the solvent and the ligand for reaction. After the reaction is completed, separate to obtain the compound represented by the trans structural formula (IIb).

55

[0156] It is apprehensible that trans-1-propenyl boronic acid reagents refer to boronic acid reagents containing trans-1-propenyl groups, including but not limited to: trans-1-propenyl boronic acid pinacol ester, trans-1-propenyl boronic acid or trans-1-propenyl fluoroborate.

60

[0157] In addition, the preferred catalyst is selected from one or more of the following reagents: 5% Pd/C, 10% Pd/C, $\text{Pd}(\text{OAc})_2$, $\text{PdCl}_2(\text{PPh}_3)_2$, $\text{Pd}(\text{PPh}_3)_4$, $\text{PdCl}_2(\text{dppf})$, $\text{PdCl}_2(\text{MeCN})_2$ and $\text{Pd}_2(\text{dba})_3$. The solvent is selected from one or more of the following reagents: methanol, ethanol, isopropanol, butanol, water, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, DME, DMF, DMSO, NMP, acetonitrile, dichloromethane, 1,2-dichloroethane, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, ethyl ether, methyl tert-butyl ether, toluene, xylene, acetone, methyl ethyl ketone and methyl cyclopentane. The ligand is selected from one or more of the following reagents: PPh_3 , BINAP, dppf, Xantphos, Xphos monophosphorus and diphosphorus ligands. Among them, the compound represented by formula (VI) can be a commercially available raw material, or can be prepared by an existing method. The compound represented by formula


(VI) is a pyrazine compound, which is currently widely sold in the market, such as CAS: 6966-01-4, 612835-51-5, 17890-77-6, and 17231-51-5, the cost of which is lower, and thus the preparation cost of the entire process route can be further reduced.

5 **3.2 Synthesis of compound represented by formula (III)**

[0158] The compound represented by formula (III) can be a commercially available raw material, or can be prepared by an existing method. Further, the compound represented by formula (III) is prepared from the compound represented by formula (II) through a cyclization reaction. That is, first, undergo a cyclization reaction, followed by a dihydroxylation reaction; or first, undergo a dihydroxylation reaction, followed by a cyclization reaction; both are allowed.

10 **3.2.1 Synthesis of the compound represented by the cis structural formula (III)**

[0159] When the alkene in the compound represented by formula (III) is a compound represented by the cis structural formula (IIIa), the compound represented by formula (IIIa) is obtained through catalytic hydrogenation of the compound represented by formula (VIII);



25 [0160] Specifically, it can include the following steps:


Mix the compound represented by formula (VIII), the catalyst and the solvent, and allow to react under a hydrogen atmosphere. After the reaction is completed, filter and concentrate to obtain the compound represented by the cis structural formula (IIIa).

[0161] Among them, the preferred catalyst can be selected from one or more of the following reagents: Lindlar catalyst, palladium/carbon, Raney nickel, platinum black and platinum dioxide; the solvent can be selected from one or more of the following reagents: tetrahydrofuran, 2-methyltetrahydrofuran, ethyl ether, methyl tertiary butyl ether, methylcyclopentyl ether, methanol, ethanol, isopropanol, acetonitrile and toluene.

[0162] Preferably, the ratio of amounts used of the compound represented by formula (VIII) to the solvent is 1 g:(1-100 mL), more preferably 1 g:(5-60 mL); the weight ratio of the compound represented by formula (VIII) to the catalyst is 1:(0.005-0.2), more preferably 1:(0.01-0.1); the pressure of hydrogen introduced is 0.1-10 MPa, more preferably 0.1-5 MPa; the reaction temperature is preferably 0-50°C.

[0163] Among them, the compound represented by formula (VIII) can be a commercially available raw material, or can be prepared by an existing method. Preferably prepare by the following method:


S3211: The compound represented by formula (VI) undergoes the Sonogashira reaction to obtain the compound represented by formula (V).



[0164] Specifically, the method described in S3111-S3112 can be used to prepare the compound represented by formula (V), which will not be repeated here.

[0165] S3212: The compound represented by formula (V) undergoes a cyclization reaction to obtain the compound represented by formula (VIII).

5



Formula (V)

Formula (VIII)

[0166] Specifically, the following methods can be used for cyclization:

[0167] The compound represented by the formula (V) undergoes a cyclization reaction with

10



15 and/or the salt of



20

(preferably guanidine salt), which is apprehensible. The

25



and/or the salt of

30



is described as above, which will not be repeated here.

[0168] Further, step S3212 can include the following steps: Mix the compound represented by formula (V),

35



40 and/or the salt of



45

, base and solvent, and heat to 50-100°C for reaction. After the reaction is completed, filter to obtain the compound represented by formula (VIII). Among them, the solvent is an alcohol solvent, preferably one or more of methanol, ethanol and isopropanol; the base can be one or more of sodium ethoxide, sodium methoxide, t-BuONa, t-BuOK and t-BuOLi; a strong base is preferred, such as sodium methoxide.

[0169] Further, step S3212 can include the following steps: Add Na to MeOH and stir until the reaction is completed.

[0170] Then add

55



and/or the salt of




5 , and stir at room temperature for 3-10 min under the protection of N₂. Then, filter the insoluble matter in the system, add the compound represented by formula (V), and heat to reflux. After the reaction is completed, allow to cool to room temperature and stir for 40 min-80 min. Filter to obtain the precipitated solid substance, which is the compound represented by formula (VIII).

10 **3.2.2 Synthesis of compound represented by the trans structural formula (III)**

[0171] When the alkene in the compound represented by formula (III) is of a trans structure, the compound represented by formula (III) can be obtained by the following method:


15 S3221: The compound represented by formula (VI) undergoes a coupling reaction to obtain the compound represented by formula (II);



20 [0172] M is H or a leaving group; preferably M is halogen, sulfonic ester, carboxylic ester or phosphoester. Among them, the sulfonate can be: methyl benzenesulfonic ester, methanesulfonic ester, trifluoromethanesulfonic ester, etc.;

25 [0173] The coupling reaction in step S3221 is the same as above, and will not be repeated here.

[0174] S3222: The compound represented by formula (II) undergoes a cyclization reaction to obtain the compound represented by formula (IIIb);



[0175] The steps of the cyclization reaction in step S3222 are the same as above, and will not be repeated here.


30 **3. The optimal reaction route**

40

Route one


[0176]

45



50

55



15 [0177] Among them, the definition of each substituent is described as above, and will not be repeated here. The preparation method of the L-erythro biopterin compound represented by formula (I) includes the following steps:

(1) The compound represented by formula (VI) undergoes the Sonogashira reaction with

20 $\equiv R_1$

$\equiv R_1$ to obtain the compound represented by formula (V);

25 (2) The compound represented by formula (V) undergoes catalytic hydrogenation to obtain the compound represented by formula (IIIa):

(3) The compound represented by formula (IIa) undergoes a dihydroxylation reaction to obtain the compound represented by formula (IVa); preferably, the chiral separation reagent set is used for chiral separation, and the chiral separation reagent set and the method are described as above:

30

35

(4) The compound represented by formula (IVa) or the compound (Formula (Iva-1)) represented by formula (IVa-1) undergoes a cyclization reaction to obtain the compound represented by formula (I-1), and the compound represented by formula (I-1) undergoes hydrolysis to obtain the L-erythro bipterin compound represented by formula (I).

[0178] In the above-mentioned (1) to (4), the specific introduction of each reaction is described as above, and will not be repeated here. It is apprehensible that when R₁ is -COOR₂ or -CONR₂, the hydrolysis step in step (4) can be omitted.


[0179] In this embodiment, the compound represented by formula (VI) is used as the starting material, which undergoes a cross-coupling reaction with alkyne, followed by catalytic hydrogenation to obtain a cis-alkene. Then, two chiral centers

45 a one coupling reaction with allyl-Cl, followed by catalytic hydrogenation to obtain a cis diol. Then, two chiral centers are constructed innovatively by systematic dihydroxylation reaction, then chiral separation and purification are performed to obtain a single enantiomer (R,S)-pyrazine propylene glycol compound, which is then cyclized to obtain the L-erythro biopterin compound. The reaction route is greatly shortened, the yield of each step is high, the atom utilization rate is high, and preparation of L-erythro biopterin by traditional condensation of 5-deoxy-L-arabinose and 2,4,5-triamino-6-hydroxypyrimidine (TAP) is avoided. Therefore, the disadvantages of low efficiency, low yield, high cost and high pollution in the existing industrial manufacturing method are comprehensively overcome.

50

Route two

[0180]




(1) The compound represented by formula (VI) undergoes the Sonogashira reaction with


[0181] In the above-mentioned (1) to (5), the specific introduction of each reaction is described as above, and will not be repeated here. It is apprehensible that when R_4 is $-COOR_5$ or $-CONR_6$, the hydrolysis step in step (5) can be omitted.

[0182] In this embodiment, the compound represented by formula (VI) is used as the starting material, which undergoes a cross-coupling reaction with alkyne, followed by sequential cyclization and catalytic hydrogenation to obtain the desired cis-alkene. Two chiral centers are constructed after dihydroxylation, followed by chiral separation and purification to obtain the desired L-erythro biopterin compound. The reaction route is greatly shortened, the yield of each step is high, the atom utilization rate is high, and preparation of L-erythro biopterin by traditional condensation of 5-deoxy-L-arabinose and 2,4,5-triamino-6-hydroxypyrimidine (TAP) is avoided. Therefore, the disadvantages of low efficiency, low yield, high cost and high pollution in the existing industrial manufacturing method are comprehensively overcome.

Route three

40





15 (1) The compound represented by formula (VI) undergoes a coupling reaction to obtain the compound represented by formula (IIb);
(2) The compound represented by formula (IIb) undergoes a dihydroxylation reaction to obtain the compound represented by formula (IVb-1) and/or formula (IVb-2);
20 (3) The compound represented by formula (IVb-1) and/or formula (IVb-2) undergoes an acetylation reaction to obtain the compound represented by formula (VIIb-1) and/or formula (VIIb-2);
(4) The compound represented by formula (VIIb-1) and/or formula (VIIb-2) undergoes Mitsunobu reaction to obtain the compound represented by formula (VIIb-3) and/or formula (VIIb-4);
(5) The compound represented by (VIIb-3) and/or formula (VIIb-4) undergoes a cyclization reaction with



and/or the salt of



35 (preferably guanidine salt), followed by hydrolysis to obtain the L-erythro biopterin compound represented by formula (I).


[0184] In the above-mentioned (1) to (4), the specific introduction of each reaction is described as above, and will not be repeated here. It is apprehensible that when R_1 is $-COOR_e$ or $-CONR_e$, the hydrolysis step in step (5) can be omitted.

40 **[0185]** In the above-mentioned method, the compound represented by formula (VI) is used as the starting material, the alkene is constructed by a coupling reaction, and the alkene is innovatively subjected to a dihydroxylation reaction, a acetylation reaction and the Mitsunobu reaction to obtain the product of desired configuration. The nature of each reaction is fully utilized, the stereoselectivity is improved, the range for selecting raw materials is expanded, and the by-product of monoacetylation and the by-product that did not flip-over in the Mitsunobu reaction can also be recovered to be raw materials by simple hydrolysis and be reused, which ensures the economy of the entire route. Meanwhile, preparation of L-erythro bipterin by traditional condensation of 5-deoxy-L-arabinose and 2,4,5-triamino-6-hydroxypyrimidine (TAP) is avoided, which avoids environmental pollution and improves production safety.


45

Specific embodiments are listed below to illustrate the present invention.


50




10 [0187] Weigh 200 mg of compound 8, 11 mg of Cul, 10 mg of PdCl_2 and 30 mg of PPh_3 , transfer into a 25-mL three-neck flask, and add 5 mL of acetonitrile. Add 0.7 mL of triethylamine and 1.1 mL of allylene (1 M in THF) while stirring at room temperature, react and stir for 16 h. Add 10 mL of water to quench the reaction, and separate the liquid. Dry and concentrate the organic layer to obtain 163 mg of compound 6, which is a crude product and will be used for the subsequent reaction. IR (cm^{-1}) ν 3400, 2226, 1647, 1487, 1192; ^1H NMR (400 MHz, DMSO-d6) δ 8.26 (s, 1H), 7.54 (s, 2H), 2.01 (s, 3H), ^{13}C NMR (101 MHz, DMSO) δ 155.61, 150.33, 128.08, 115.71, 111.16, 88.27, 76.62, 4.18. HRMS m/z (ESI+) $\text{C}_8\text{H}_7\text{N}_4^+$ requires: 159.0667; found: 159.0671.



20 [0188] Add 62 mg of Na to 10 mL of MeOH, and stir until the reaction is completed. Add 226 mg of guanidine HCl and stir at room temperature for 5 min under the protection of N_2 . Filter and remove the insolubles in the system, and add 163 mg of compound 6. Heat to reflux, and stir for 18 h. After cool the reaction system to room temperature, and stir for 1 h. Filter to obtain the yellow crystals precipitated from the system, which are the compound 5 (weight: 144 mg, purity: > 99%, yield of the above two steps: 71.6%); IR (cm^{-1}) ν 3421, 3102, 1635, 1456, 1507, 1063; ^1H NMR (500 MHz, DMSO-d6) δ 8.91 (s, 1H), 7.08 (s, 2H), 6.33 (s, 2H), 2.06 (s, 3H); ^{13}C NMR (125 MHz, DMSO) δ 163.83, 162.42, 155.36, 146.65, 136.10, 119.12, 91.24, 83.52, 4.73. HRMS m/z (ESI+) $\text{C}_9\text{H}_9\text{N}_6^+$ requires: 201.4358; found: 201.4359.



40 [0189] Add 144 mg of compound 5 to 20 mL of THF, and dissolve by heating to 50°C. Add 150 mg of Lindlar Pd, replace with H_2 , and stir for 3 days at 1 atm. Filter and remove the catalyst. Concentrate to obtain compound 4 (120 mg, purity: 90%, yield: 83%); IR (cm^{-1}) ν 3294, 1646, 1508, 1479, 1380, 1046; ^1H NMR (500 MHz, DMSO) δ 8.49 (s, 1H), 7.28 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 9.5 Hz, 1H), 6.75-6.69 (m, 1H), 6.58 (s, 2H), 6.23 (dq, J = 10.5, 6.0 Hz, 1H), 1.92 (dd, J = 6.0, 1.1 Hz, 3H). ^{13}C NMR (125 MHz, DMSO) δ 161.42, 154.82, 147.13, 144.39, 129.56, 126.01, 118.45, 17.04, 16.95. HRMS m/z (ESI+) $\text{C}_9\text{H}_{11}\text{N}_6^+$ requires: 203.2210; found: 203.2208.



50 [0190] For the dihydroxylation of compound 4, including the following methods:

55 1) Sharpless asymmetric dihydroxylation reaction

55 [0191] Weigh 5.2 g of AD-mix- α , transfer into a 250-mL three-neck flask, and add 10 mL of water and 10 mL of tert-butyl alcohol. Add 143 mg of MsNH_2 and 120 mg of compound 4 while stirring. Allow to react at room temperature, and stir for 16 h. Filter and remove the insolubles. Separate the liquid, extract the aqueous phase three times with ethyl acetate (30 mL \times 3), and combine the organic phases. Dry over Na_2SO_4 , and concentrate to obtain 151 mg of a dark brown oily substance. Perform chiral preparation with the crude product to obtain a single chiral intermediate 2 (54 mg, with a yield of 42%).


2) Dihydroxylation with KMnO_4

[0192] Add 100 mg of compound 4 to 10 mL of THF, cool the system to 0°C, and add 10 mL of 1% potassium permanganate aqueous solution (pH = 12) and 5 mg of tetrabutylammonium chloride. React at 0°C and stir overnight. Separate the liquid, extract the aqueous phase with EA (5 mL × 3), and combine the organic phases. Dry over Na_2SO_4 , filter, and concentrate. Wash with methanol to obtain 86 mg of a yellow solid. Perform chiral preparation with the crude product to obtain a single chiral intermediate 2 (28 mg, with a yield of 22%).

3) Dihydroxylation with Fe catalyst

[0193] Dissolve 100 mg of compound 4 in 10 mL of THF. Add 5 mL of an aqueous solution containing the catalyst $[\text{Fe}^{\text{III}}(\text{L-N4Me}_2)\text{Cl}_2]^+$ 3.5 mol% oxone (2 equiv) and NaHCO_3 (6 equiv), react at room temperature and stir overnight. Separate the liquid, and collect the organic phase. Concentrate, and wash with methanol to obtain 76 mg of a yellow solid crude product. Perform chiral preparation with the crude product to obtain a single chiral intermediate 2 (16 mg, with a yield of 12.4%).


[0194] IR (cm^{-1}) ν 3288, 1655, 1514, 1469, 1379, 1058; ^1H NMR (500 MHz, DMSO-d6) δ 8.72 (s, 1H), 7.63 (s, 2H), 6.58 (s, 2H), 5.45 (s, 1H), 4.68 (s, 1H), 4.41 (d, J = 6.3 Hz, 1H), 3.84 (p, J = 6.2 Hz, 1H), 1.11 (d, J = 6.2 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 162.93, 162.81, 155.25, 149.73, 149.60, 120.48, 76.43, 69.73, 19.55; HRMS m/z (ESI+) $\text{C}_9\text{H}_{13}\text{N}_6\text{O}_2^+$ requires: 237.1095; found: 237.1094.



[0195] Suspend the obtained 54 mg of compound 2 in 5 mL of NaOH aqueous solution (80 mg) for reaction. Heat to 78°C, and stir for 3 h. Cool to room temperature, and adjust the pH to 5-6 by adding HCOOH dropwise. Filter to obtain the precipitated crystals, which are compound 1, i.e., the L-erythro biopterin compound (51 mg, purity > 99%, yield > 99%); IR (cm^{-1}) ν 3249, 1701, 1537, 1490, 1367, 1127; ^1H NMR (500 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m/z (ESI+) $\text{C}_9\text{H}_{12}\text{O}_3\text{N}_5^+$ requires: 238.0935; found: 238.0935.


35 Embodiment 2

[0196]



[0197] Disperse 200 mg of compound 5 in 5 mL of NaOH aqueous solution (50 mg), heat to 78°C, and stir for 1 h. Adjust the pH to 5-6 by adding acetic acid dropwise, filter to obtain the precipitated solids and wash with methanol to obtain compound 5-1 (152 mg, with a purity of 98%, and a yield of 76%);

[0198] Dissolve 152 mg of compound 5-1 in 5 mL of a combined solution of MeOH/DCM=1/1, and stir thoroughly to dissolve. Add 100 mg of Lindlar Pd, replace with H_2 (1 atm), and stir at room temperature for 3 days. Filter and remove the catalyst. Concentrate the solvent to obtain compound 3 (150 mg, purity: 95%, yield: 93%); ^1H NMR (500 MHz, DMSO) δ 12.3 (s, 1H), 8.53 (s, 1H), 6.49 (s, 2H), 2.04 (s, 3H). ^{13}C NMR (125 MHz, DMSO) δ 161.85, 156.13, 150.79, 148.55, 136.37, 127.07, 92.12, 85.24, 4.59. HRMS m/z (ESI+) $\text{C}_9\text{H}_{10}\text{N}_5\text{O}^+$ requires: 203.2050, found: 203.2051.



[0199] For the dihydroxylation of compound **3**, including the following methods:

1) Sharpless asymmetric dihydroxylation reaction

[0200] Weigh 2.6 g of AD-mix- α , transfer into a 100-mL three-neck flask, and add 5 mL of H_2O and 5 mL of t-BuOH. Add 70 mg of $MgNH_2$ and 150 mg of compound **3** while stirring. Allow to react at room temperature, and stir for 16 h. Filter and remove the insolubles. Separate the liquid, extract the aqueous phase three times with 2-MeTHF (30 mL \times 3), and combine the organic phases. Dry over Na_2SO_4 , and concentrate to obtain 56 mg of a dark brown oily substance. Perform chiral preparation with the crude product to obtain a single chiral compound **1** (19 mg, with a yield of 11%).

2) Dihydroxylation with $KMnO_4$

[0201] Prepare 10 mL of 1% potassium permanganate aqueous solution (pH 12), and add 150 mg of compound **3**. React at 0°C and stir overnight. Add Na_2SO_3 to quench the reaction, adjust the pH to 5-7 by adding acetic acid dropwise, and filter the product. Perform chiral preparation with the crude product to obtain a single chiral compound **1** (40 mg, with a yield of 21%).


3) Dihydroxylation with Fe catalyst

[0202] Add 150 mg of compound **3** to 5 mL of an aqueous solution containing the catalyst $[Fe^{III}(L-N4Me_2)Cl_2]^+$ 3.5 mol% oxone (2 equiv) and $NaHCO_3$ (6 equiv), react at room temperature and stir overnight. Add Na_2SO_3 to quench the reaction, and adjust the pH to 5-7 by adding acetic acid dropwise. Filter to obtain the precipitated product. Perform chiral preparation with the crude product to obtain a single chiral compound **1** (15 mg, with a yield of 8.7%).


[0203] IR (cm^{-1}) ν 3249, 1701, 1537, 1490, 1367, 1127; 1H NMR (500 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m/z (ESI+) $C_9H_{12}O_3N_5^+$ requires: 238.0935; found: 238.0935.

Embodiment 3


[0204]



[0205] Weigh 200 mg of compound **8**, 11 mg of CuI , 10 mg of $PdCl_2$ and 30 mg of PPh_3 , transfer into a 25-mL three-neck flask, and add 5 mL of acetonitrile. Add 0.7 mL of triethylamine and 1.1 mL of allylene (1 M in THF) while stirring at room temperature, react and stir for 16 h. Add 10 mL of water to quench the reaction, and separate the liquid. Dry the organic layer, and concentrate to obtain 160 mg of compound **6**, which is a crude product and will be used for the subsequent reaction.



[0206] Place the obtained 500 mg of compound **6** in a high-pressure reaction kettle. Add 500 mg of Lindlar catalyst and 10 mL of THF. Replace with H_2 for three times, and stir at room temperature for 16 h. Filter and remove the catalyst. Concentrate to obtain 400 mg of compound **5a**; IR (cm^{-1}) ν 3401, 3202, 2222, 1644, 1492, 1515, 1172; 1H NMR (500 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.33 (s, 2H), 6.30 (dq, J = 11.7, 1.8 Hz, 1H), 5.88 (dq, J = 11.7, 7.3 Hz, 1H), 2.01 (dd, J = 7.3, 1.8 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 154.87, 147.91, 141.32, 129.95, 124.29, 116.05, 109.58, 14.88; HRMS m/z (ESI+) $C_8H_9N_4^+$ requires: 161.0822; found: 161.0821.



[0207] For the dihydroxylation of compound **5a**, including the following methods:

1) Sharpless asymmetric dihydroxylation reaction


[0208] Weigh 6.5 g of AD-mix- α , transfer into a 250-mL three-neck flask, and add 10 mL of water and 10 mL of tert-butyl alcohol. Add 180 mg of MsNH_2 and 350 mg of compound **5a** while stirring. Allow to react at room temperature, and stir for 16 h. Filter and remove the insolubles. Separate the liquid, extract the aqueous phase three times with ethyl acetate (30 mL \times 3), and combine the organic phases. Dry over NaS_2O_4 , and concentrate to obtain 200 mg of a dark brown oily substance. Perform chiral preparation with the crude product to obtain a single chiral intermediate **4a**; IR (cm^{-1}) ν 3374, 3196, 2236, 1655, 1572, 1496, 1065; ^1H NMR (500 MHz, DMSO-d6) δ 8.30 (s, 1H), 7.17 (s, 2H), 5.42 (d, J = 5.1 Hz, 1H), 4.57 (d, J = 5.3 Hz, 1H), 4.21 (dd, J = 6.0, 5.1 Hz, 1H), 3.84–3.75 (m, 1H), 1.04 (d, J = 6.2 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 156.21, 146.77, 146.63, 116.26, 108.70, 76.21, 69.18, 19.34; HRMS m/z (ESI+) $\text{C}_8\text{H}_{11}\text{N}_4\text{O}_2^+$ requires: 195.0877; found: 195.0878.

2) Dihydroxylation with KMnO_4 :


[0209] Add 80 mg of compound **5a** to 10 mL of THF, cool the system to 0°C, and add 10 mL of 1% potassium permanganate aqueous solution (pH=12) and 5 mg of tetrabutylammonium chloride. React at 0°C and stir overnight. Separate the liquid, extract the aqueous phase with EA (5 mL × 3), and combine the organic phases. Dry over Na_2SO_4 , filter and concentrate. Then wash with methanol to obtain 88 mg of a yellow solid. Perform chiral preparation with the crude product to obtain a single chiral intermediate **4a** (31 mg, with a yield of 32%).

3) Dihydroxylation with Fe catalyst

[0210] Dissolve 80 mg of compound **5a** in 10 mL of THF. Add 5 mL of an aqueous solution containing the catalyst $[\text{FeIII}(\text{L-N4Me}_2)\text{Cl}_2]^+$ 3.5 mol% oxone (2 equiv) and NaHCO_3 (6 equiv). React at room temperature and stir overnight. Separate the liquid, and collect the organic phase. Concentrate, and wash with methanol to obtain 64 mg of a yellow solid crude product. Perform chiral preparation with the crude product to obtain a single chiral intermediate **4a** (13 mg, with a yield of 17%).



[0211] Add 62 mg of Na to 10 mL of MeOH, and stir until the reaction is completed. Add 226 mg of guanidine HCl and stir at room temperature for 5 min under the protection of N₂. Filter and remove the insolubles in the system. Add 200 mg of single chiral intermediate **4a**. Heat to reflux, and stir for 18 h. Cool the reaction system to room temperature, and stir for 1 h. Filter to obtain the yellow crystals precipitated from the system, which are compound **2** (weight: 150 mg, purity > 99%, yield: 68%);



[0212] Suspend the obtained 100 mg of compound **2** in 10 mL of NaOH aqueous solution (160 mg), heat to 78°C and stir for 3 h for reaction. Cool to room temperature, and adjust the pH to 5-6 by adding HCOOH dropwise. Filter to obtain the precipitated crystals, which are compound **1**, i.e., the L-erythro biopterin compound (100 mg, purity > 99%, yield >


99%); IR (cm^{-1}) ν 3249, 1701, 1537, 1490, 1367, 1127; ^1H NMR (500 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m/z (ESI+) $\text{C}_9\text{H}_{12}\text{O}_3\text{N}_5^+$ requires: 238.0935; found: 238.0935.

5

Embodiment 4


[0213]

10



[0214] Weigh 200 mg of compound 8, 104 mg of E-propenyl-boric acid, 37 mg of Pd(dppf)Cl₂, 500 mg of K₂CO₃, and dissolve in 1,4-diox/H₂O (v/v=3 mL/2 mL) for reaction. Heat to reflux, and stir for 3 h. The reaction, which is monitored by TLC, is completed. Separate the liquid, extract the aqueous phase with EA, and combine the organic phases. Dry over Na₂SO₄, and perform chromatography with the concentration column (EA/heptane = 1/5-1/3) to obtain a yellow solid 5b (100 mg); IR (cm⁻¹) v 3384, 2231, 1667, 1574, 1498, 1316, 1166; ¹H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81-3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); ¹³C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m/z (ESI+) C₈H₁₁N₄O₂⁺ requires: 195.0879; found: 195.0877.

28



30

[0215] For the dihydroxylation of compound **5b**, including the following methods:

1) Sharpless asymmetric dihydroxylation reaction

[0216] Weigh 7.0 g of AD-mix- α , disperse in t-BuOH/H₂O (30 mL/30 mL), and stir at 0°C for 5 min. Add 475 mg of MnNH₂, and stir at 0°C for 5 min. Then add 800 mg of compound **5b**, heat to 4°C, react and stir for 2 d. After the reaction, which is monitored by HPLC, is completed, add 10 g of Na₂SO₃ into the system, and stir at room temperature for 30 min. Filter and wash the filtration residues with 50 mL of EA. After the filtrate is separated, extract the aqueous phase with EA (50 mL \times 3). Combine the organic phases, dry over Na₂SO₄, and purify by column chromatography (HEP:EA=5:1:0:1) to obtain a light-yellow solid **4b** (1.08 g, yield > 99%, purity = 98%, ee = 94%); IR (cm⁻¹) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; ¹H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, *J* = 5.4 Hz, 1H), 4.54 (d, *J* = 5.4 Hz, 1H), 4.26 (t, *J* = 5.0 Hz, 1H), 3.81–3.71 (m, 1H), 1.00 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m/z (ESI+) C₈H₁₁N₄O₂⁺ requires: 195.0879; found: 195.0877.

45

2) Dihydroxylation with KMnO_4


[0217] Add 80 mg of compound **5b** to 10 mL of THF, cool the system to 0°C, and add 10 mL of 1% potassium permanganate aqueous solution (pH=12) and 5 mg of tetrabutylammonium chloride. React at 0°C and stir overnight. Separate the liquid, extract the aqueous phase with EA (5 mL × 3), and combine the organic phases. Dry over Na_2SO_4 , filter and concentrate. Then wash with methanol to obtain 91 mg of a yellow solid. Perform chiral preparation with the crude product to obtain a single chiral intermediate **4b** (33 mg, with a yield of 34%).

3) Dihydroxylation with Fe catalyst


[0218] Dissolve 80 mg of compound **5b** in 10 mL of THF. Add 5 mL of an aqueous solution containing the catalyst $[\text{FeIII}(\text{L-N4Me}_2)\text{Cl}_2]^+$ 3.5 mol% oxone (2 equiv) and NaHCO_3 (6 equiv). React at room temperature and stir overnight. Separate the liquid, and collect the organic phase. Concentrate, and wash with methanol to obtain 64 mg of a yellow solid crude product. Perform chiral preparation with the crude product to obtain a single chiral intermediate **4b** (15 mg,

with a yield of 20%).

[0219] IR (cm^{-1}) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; ^1H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m/z (ESI+) $\text{C}_8\text{H}_{11}\text{N}_4\text{O}_2^+$ requires: 195.0879; found: 195.0877.




[0220] Disperse 800 mg of compound 4b in 100 mL of ACN, and stir thoroughly. Add 1.48 g of $\text{H}_3\text{CC}(\text{OEt})_3$ and 39 mg of PTSA, stir until they are completely dissolved, and continue stirring for 30 min. Then add 1 mL of H_2O to the system, and continue stirring for 30 min. After the reaction of raw materials, which is monitored by TLC, is completed, two kinds of products are generated. Directly add silica gel to the system, stir, and perform column chromatography to obtain 400 mg of compound 3b-2, and 421 mg of a mixture of compounds 3b-1 and 3b-2. Add the mixture of compounds 3b-1 and 3b-2 to NH_3/MeOH solution, and stir for 30 min. Compound 4b is generated. Repeat the above-mentioned monoacetylation process to obtain 260 mg of compound 3b-2. A total of 660 mg of compound 3b-2 is obtained from the two reactions, with a purity of 90% and a yield of 61%; Data in the spectra of compound 3b-2: IR (cm^{-1}) ν 3452, 3340, 2223, 1697, 1616, 1482, 1372, 1044; ^1H NMR (500 MHz, DMSO-d6) δ 8.33 (s, 1H), 7.29 (s, 2H), 5.77 (d, J = 5.3 Hz, 1H), 5.03 (qd, J = 6.5, 5.1 Hz, 1H), 4.53 (t, J = 5.3 Hz, 1H), 1.93 (s, 3H), 1.10 (d, J = 6.5 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 169.75, 156.23, 146.23, 144.84, 115.98, 109.15, 73.02, 72.05, 20.88, 16.00. HRMS m/z (ESI+) $\text{C}_{10}\text{H}_{12}\text{O}_3\text{N}_4\text{Na}^+$ requires: 259.0802; found: 259.0801.




[0221] Weigh 500 mg of compound 3b-2, 732 mg of naproxen, 834 mg of PPh_3 , and dissolve in 30 mL of THF. Add 0.63 mL of DIAD dropwise at 0°C, react and stir overnight. After the reaction is completed, which is monitored by HPLC, add saturated NaHCO_3 aqueous solution into the system to quench the reaction. Separate the liquid, and extract the aqueous phase with EA (20 mL \times 2). Combine the organic phases, dry over Na_2SO_4 , and concentrate. Perform column chromatography (EA/Heptane = 1/2) to obtain compound 2b-1 (272 mg, with a purity of 97%, and a yield of 28%) and compound 2b-2 (610 mg), respectively. Add the obtained compound 2b-2 to NH_3/MeOH solution, stir for 1 h to obtain 260 mg of compound 4b again, which is recovered and used as raw material in the upstream reaction.

[0222] Data in the spectra of compound 2b-1: IR (cm^{-1}) ν 3331, 2224, 1740, 1630, 1233; ^1H NMR (500 MHz, DMSO-d6) δ 7.90-7.69 (m, 4H), 7.48-7.36 (m, 3H), 7.34-7.23 (m, 1H), 7.19-7.10 (m, 1H), 5.69 (d, J = 4.2 Hz, 1H), 5.28-5.13 (m, 1H), 4.05 (q, J = 7.0 Hz, 1H), 3.86 (s, 3H), 1.89 (s, 3H), 1.51 (d, J = 7.1 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 172.77, 169.44, 157.23, 156.29, 145.61, 139.20, 134.99, 133.36, 129.14, 128.36, 126.92, 126.27, 125.81, 118.82, 115.55, 109.62, 105.74, 74.45, 69.72, 55.15, 44.36, 20.64, 17.80, 14.74. HRMS m/z (ESI+) $\text{C}_{24}\text{H}_{24}\text{O}_5\text{N}_4\text{Na}^+$ requires: 471.1639; found: 471.1637.



10 [0223] Weigh 77 mg of Na, add into 30 mL of methanol, and stir thoroughly until the reaction is completed. Transfer 3 mL of the above solution, add 32 mg of guanidine HCl, and stir for 5 min under the protection of N₂. Filter and remove the insolubles. Add 50 mg of compound 2b-1 for reaction. Heat to reflux and stir overnight. Bright yellow crystals are precipitated. Filter to obtain the precipitated crystals, which are compound 2 (15.3 mg, with a yield of 58%); IR (cm⁻¹) ν 3288, 1655, 1514, 1469, 1379, 1058; ¹H NMR (500 MHz, DMSO-d6) δ 8.72 (s, 1H), 7.63 (s, 2H), 6.58 (s, 2H), 5.45 (s, 1H), 4.68 (s, 1H), 4.41 (d, *J* = 6.3 Hz, 1H), 3.84 (p, *J* = 6.2 Hz, 1H), 1.11 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (126 MHz, DMSO) δ 162.93, 162.81, 155.25, 149.73, 149.60, 120.48, 76.43, 69.73, 19.55; HRMS m/z (ESI+) C₉H₁₃N₆O₂⁺ requires: 237.1095; found: 237.1094.


15



25 [0224] Suspend the obtained 100 mg of compound 2 in 10 mL of NaOH aqueous solution (160 mg), heat to 78°C and stir for 3 h for reaction. Cool to room temperature, and adjust the pH to 5-6 by adding HCOOH dropwise. Filter to obtain the precipitated crystals, which are compound 1, i.e., the L-erythro bipterin compound (100 mg, purity > 99%, yield > 99%);

30 Embodiment 5

[0225]



40 [0226] For the dihydroxylation of compound 5b, including the following methods:

1) Sharpless asymmetric dihydroxylation reaction

45 [0227] Weigh 7.0 g of AD-mix-β, disperse in t-BuOH/H₂O (30 mL/30 mL), and stir at 0°C for 5 min. Add 475 mg of MsNH₂, and stir at 0°C for 5 min. Then add 800 mg of compound 5b, heat to 4°C, react and stir for 2 d. After the reaction, which is monitored by HPLC, is completed, add 10 g of Na₂SO₃ to the system, and stir at room temperature for 30 min. Filter and wash the filtration residues with 50 mL of EA. After the filtrate is separated, extract the aqueous phase with EA (50 mL \times 3), and combine the organic phases. Dry over Na₂SO₄, and purify by column chromatography (HEP:EA = 5:1-0:1) to obtain a light-yellow solid 4b-1 (979 mg, yield > 99%, purity = 98%, ee = 92%);

50 [0228] IR (cm⁻¹) ν 3374, 2230, 1668, 1570, 1486, 1166; ¹H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, *J* = 5.4 Hz, 1H), 4.54 (d, *J* = 5.4 Hz, 1H), 4.26 (t, *J* = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m/z (ESI+) C₈H₁₁N₄O₂⁺ requires: 195.0879; found: 195.0877.

55 2) Dihydroxylation with KMnO₄

[0229] Add 80 mg of compound 5b to 10 mL of THF, cool the system to 0°C, and add 10 mL of 1% potassium permanganate aqueous solution (pH=12) and 5 mg of tetrabutylammonium chloride. React at 0°C and stir overnight.


Separate the liquid, extract the aqueous phase with EA (5 mL \times 3), and combine the organic phases. Dry over Na_2SO_4 , filter and concentrate. Then wash with methanol to obtain 91 mg of a yellow solid. Perform chiral preparation with the crude product to obtain a single chiral intermediate **4b-1** (29 mg, with a yield of 30%).

5 **3) Dihydroxylation with Fe catalyst**

[0230] Dissolve 80 mg of compound **5b** in 10 mL of THF. Add 5 mL of an aqueous solution containing the catalyst $[\text{Fe}(\text{III})(\text{L-N4Me}_2)\text{Cl}_2]^+$ 3.5 mol% oxone (2 equiv) and NaHCO_3 (6 equiv). React at room temperature and stir overnight. Separate the liquid, and collect the organic phase. Concentrate, and wash with methanol to obtain 64 mg of a yellow solid crude product. Perform chiral preparation with the crude product to obtain a single chiral intermediate compound **4b-1** (12 mg, with a yield of 16%); IR (cm^{-1}) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; ^1H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81-3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m/z (ESI+) $\text{C}_8\text{H}_{11}\text{N}_4\text{O}_2^+$ requires: 195.0879; found: 195.0877.

15


20



[0231] Disperse 800 mg of compound **4b-1** in 100 mL of ACN, and stir thoroughly. Add 1.48 g of $\text{H}_3\text{CC}(\text{OEt})_3$ and 39 mg of PTSA, stir until they are completely dissolved. Continue to stir for 30 min, then add 1 mL of H_2O into the system, and stir for 30 min. After the reaction, which is monitored by TLC, is completed, two kinds of products are generated. Directly add silica gel to the system, stir, and perform chromatography to obtain 200 mg of compound **3b-3**, and 611 mg of a mixture of compound **3b-4** and **3b-3**. Add the mixture of compound **3b-4** and **3b-3** to NH_3/MeOH solution, and stir for 30 min. Compound **4b-1** is generated. Repeat the above-mentioned monoacetylation process to obtain 240 mg of compound **3b-3**. A total of 440 mg of compound **3b-4** is obtained from the two reactions, with a purity of 90% and a yield of 41%. IR (cm^{-1}) ν 3426, 2220, 1683, 1606, 1485, 1373; ^1H NMR (500 MHz, DMSO-d6) δ 8.28 (s, 1H), 7.38 (s, 2H), 5.38 (d, J = 6.0 Hz, 1H), 4.04-3.96 (m, 1H), 2.08 (s, 3H), 0.98 (d, J = 6.4 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 170.00, 156.37, 146.69, 141.44, 115.84, 109.67, 77.50, 66.91, 20.81, 19.06. HRMS m/z (ESI+) $\text{C}_{10}\text{H}_{12}\text{O}_3\text{N}_4\text{Na}^+$ requires: 259.0802; found: 259.0803.

35


40



[0232] Weigh 100 mg of compound **3b-3**, 147 mg of naproxen, 167 mg of PPh_3 , and dissolve in 10 mL of THF. Add 0.2 mL of DIAD dropwise at 0°C , react and stir overnight. After the reaction, which is monitored by HPLC, is completed, add saturated NaHCO_3 aqueous solution into the system to quench the reaction. Separate the liquid, and extract the aqueous phase with EA (20 mL \times 2). Combine the organic phases, dry over Na_2SO_4 , perform chromatography of the concentration column (EA/Heptane=1/2), to obtain compound **2b-3** (52 m, with a purity of 97%, and a yield of 27%).


50

55



[0233] Weigh 77 mg of Na, add into 30 mL of methanol, and stir thoroughly until the reaction is completed. Transfer 3 mL of the above solution, add 32 mg of guanidine HCl, and stir for 5 min under the protection of N_2 . Filter and remove


the insolubles, add 50 mg of compound **2b-3** for reaction. Heat to reflux, and stir overnight. Bright yellow crystals are precipitated. Filter to obtain the precipitated crystals, which are compound **2** (16.8 mg, with a yield of 64%); IR (cm^{-1}) ν 3329, 2222, 1736, 1625, 1225; ^1H NMR (500 MHz, DMSO-d6) δ 7.99-7.65 (m, 4H), 7.51-7.36 (m, 3H), 7.34-7.21 (m, 1H), 7.20-7.08 (m, 1H), 5.58 (d, J = 4.2 Hz, 1H), 5.31-5.10 (m, 1H), 4.09 (q, J = 7.0 Hz, 1H), 3.74 (s, 3H), 1.56 (s, 3H), 1.49 (d, J = 7.1 Hz, 3H), 1.10 (d, J = 6.6 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 174.53, 167.36, 157.37, 156.89, 148.58, 138.26, 134.93, 130.35, 129.54, 127.87, 126.92, 126.27, 123.21, 117.72, 112.51, 106.42, 103.14, 73.25, 66.71, 55.36, 47.63, 21.64, 19.83, 12.79. HRMS m/z (ESI+) $\text{C}_{24}\text{H}_{24}\text{O}_5\text{N}_4\text{Na}^+$ requires: 471.1639; found: 471.1638.




15 [0234] Suspend the obtained 100 mg of compound **2** in 10 mL of NaOH aqueous solution (160 mg), heat to 78°C and stir for 3 h for reaction. Cool to room temperature, and adjust the pH to 5-6 by adding HCOOH dropwise. Filter to obtain the precipitated crystals, which are compound **1**, i.e., the L-erythro biopterin compound (100 mg, purity > 99%, yield > 99%);

20 **Embodiment 6**


[0235]



30 [0236] Dissolve 10 g of compound **8** (50 mmol), 475 mg of Cul (2.5 mmol), 440 mg of PdCl_2 (2.5 mmol), 1.3 g of TPP (5 mmol), 25.3 g of TEA (250 mmol) and 55 mL of allylene (1 M) in 250 mL of acetonitrile, react and stir at room temperature for 16 h. After the raw materials are completely converted to product, which is monitored by HPLC, add 100 mL of H_2O , wash and separate the liquid. Extract the aqueous phase with EA (25 mL × 3). Collect the organic phases, dry over Na_2SO_4 , and perform column chromatography (EA:Heptane = 3:1) to obtain compound **6**, which are yellow crystals, with a weight of 7.8 g and a yield of 98.7%.




45 [0237] Weigh 2 g of compound **6** (12.5 mmol), and transfer into a hydrogenation kettle. Add 20 mL of 2-MeTHF to dissolve, and add 20 mg of Lindlar Pd. Replace with H_2 , pressurize to 0.2 MPa and stir at room temperature. After the reaction of raw materials, which is monitored by HPLC, is just completed, filter to remove Lindlar Pd, and concentrate. Perform column chromatography (EA:Heptane = 1:3) to obtain 1.9 g of yellow crystals, which are compound **5a**. IR (cm^{-1}) ν 3401, 3202, 2222, 1644, 1492, 1515, 1172; ^1H NMR (500 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.33 (s, 2H), 6.30 (dq, J = 11.7, 1.8 Hz, 1H), 5.88 (dq, J = 11.7, 7.3 Hz, 1H), 2.01 (dd, J = 7.3, 1.8 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 154.87, 147.91, 141.32, 129.95, 124.29, 116.05, 109.58, 14.88; HRMS m/z (ESI+) $\text{C}_8\text{H}_9\text{N}_4^+$ requires: 161.0822; found: 161.0821.




[0238] Dissolve 1.5 mg of $\text{K}_2\text{OsO}_4 \cdot 2\text{H}_2\text{O}$ (4 μmol), 20 mg of DHQ-IND (40 μmol), 840 mg of K_2CO_3 (6 mmol) and 2

g of $K_3[Fe(CN)_6$] (6 mmol) in $H_2O/t\text{-BuOH}$ (10 mL/10 mL), and stir at room temperature until they are completely dissolved. Then add compound 5a, react and stir at room temperature overnight (approximate 18 h). After the reaction is completed, which is monitored by HPLC, separate the liquid, collect the organic phase, and extract the aqueous phase with 2-MeTHF until no residue remains. Dry over Na_2SO_4 , filter, and concentrate. Perform column chromatography to obtain 110 mg of white crystals, which is a mixture of compounds **4a** and **4b** (er=62:38).




15 [0239] Disperse 220 mg of the above obtained mixture of compounds **4a** and **4b** (er = 62:38) in 5 mL of methylbenzene, and heat to reflux. Add 225 mg of isopropyl borate. After the system is dissolved to be clear, continue to reflux for 30 min. Inject 121 mg of D-Prolinol, and reflux for 30 min. Cool to room temperature, and filter to obtain the precipitated solid. Wash the filter cake thoroughly with 2-MeTHF, and collect the filter cake to obtain compound **3a**, which are white crystals, with a weight of 144 mg, a yield of 42%, a chemical purity of 99% and the diastereomer ratio (dr) is **3a**:**3b** = 96:4.


20



30 [0240] Disperse 1 g of compound **3a** (dr = 99:1) with 10 mL of 2-MeTHF, add 5 mL of saturated K_2CO_3 , stir until it is completely dissolved. Separate the liquid, extract the aqueous phase with 2-MeTHF (10 mL \times 3), and combine the organic phases. Dry over Na_2SO_4 , filter, and concentrate. Perform column chromatography (EA:Heptane = 1:3) to obtain 620 mg of white crystals, which are compound **4a** (purity: 99%, ee: 98%).




40 [0241] Dissolve 638 mg of guanidine HCl (7.3 mmol) in 7 mL of methanol, add 1.4 mL of sodium methoxide (5 M in MeOH), and stir for 10 min. Filter and remove the precipitated solid. Collect the filtrate, and add 320 mg of compound **4a** (1.67 mmol, ee > 99%). Heat and reflux overnight. Cool to room temperature and filter the collected filter cake to obtain 250 mg of yellow crystals, which are compound **2** (ee > 99.9%, purity: 99%, yield: 64%).



50 [0242] Dissolve 638 mg of guanidine HCl (7.3 mmol) in 7 mL of methanol, add 1.4 mL of sodium methoxide (5 M in MeOH), and stir for 10 min. Filter and remove the precipitated solid. Collect the filtrate, and add 500 mg of compound **3a** (1.65 mmol, **3a**:**3b** = 94:6). Heat and reflux overnight. Cool to room temperature, filter and collect the filtration cake to obtain 244 mg of yellow crystals, which are compound **2** (ee>99.9%, purity: 99%, yield: 63%).


55 [0243] IR (cm^{-1}) ν 3249, 1701, 1537, 1490, 1367, 1127; 1H NMR (500 MHz, DMSO- d_6) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); ^{13}C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m/z (ESI+) $C_9H_{12}O_3N_5^+$ requires: 238.0935; found: 238.0935.



[0244] Disperse 89 mg of compound 2 (with a purity of 99%, ee = 99.9%) in 5 mL of NaOH aqueous solution (15 mg), heat to 50°C and stir for 4 h. After the conversion rate of the reaction, which is controlled in-process by HPLC, reaches approximate 90%, supplement 100 mg of NaOH, and heat to 78°C. After the reaction is completed, add 10 mg of activated carbon for decoloration, filter, and wash with 1 mL of butyl alcohol. Separate the liquid, and collect the aqueous phase. Neutralize to pH 7 with 1 M diluted hydrochloric acid to obtain compound 1, which is a white solid, with a weight of 78 mg, a purity of 99%, a yield of 87%, and a ee of 99.9%. IR (cm⁻¹) v 3249, 1701, 1537, 1490, 1367, 1127; ¹H NMR (500 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); ¹³C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m/z (ESI+) C₉H₁₂O₃N₅⁺ requires: 238.0935; found: 238.0935.

Embodiment 7


[0245] Prepare a racemic mixture of compounds **4a** and **4b** as per Embodiment 1;



[0246] Dissolve 100 mg of the racemic mixture of compounds **4a** and **4b** in 5 mL of acetonitrile, and add 117 mg of isopropyl borate. Reflux and stir for 30 min. Dissolve 93.4 mg of L-phenylglycinol in acetonitrile, and add into the system. Continue to reflux for about 15 min. Precipitates are formed. Filter to obtain 72 mg of product **9a**, which are white crystals, with a chemical purity of 99%, a diastereomer ratio (dr) of **9a**:**9b** = 99.2:0.8.

Validation test of configuration

[0247] Obtain the XRD data of product (Compound **3a**,



) formed after separation of L-prolinol.

[0248] The detection instrument is D8 Venture and the parameters of instrument are shown in Table 1 as below:

Table 1.

Light source: Cu target	X-ray: Cu-K α (=1.54018 Å)
Detector: CMOS area detector	Resolution: 0.80 Å
Current and voltage: 50 KV, 1.2 A	Exposure time: 5 s
Distance from area detector to sample: 40 mm	Test temperature: 173 (2) K

[0249] Structure elucidation and refinement process:

After integration and reduction were performed to the diffraction data using the SAINT program, empirical absorption correction was performed to the data using the SADABS program; the single crystal structure was elucidated by the

direct method using SHELXT2014, and the structure was refined using the least squares method. The hydrogen atom refinement was achieved by isotropic computational processing, the hydrogen atom on C-H was obtained by computational hydrogenation, and its refinement was performed using the riding model.

[0250] Diffraction intensity data were collected with a D8 Venture diffractometer under the following conditions: Cu target (Cu-K α (= 1.54018 Å)), graphite monochromator, diameter of single guide tube: Φ = 0.50 mm, distance from crystal to the COMS detector: d = 40 mm, resolution: 0.80 Å, tube pressure: 50 KV, tube flow: 1.2 mA, scan mode: Φ and ω scan, the total number of diffraction points collected: 6738, the number of separate diffraction points: 2751, and the number of viewing point ($|F| \geq 2\sigma|F|$): 2709. The Flack constant is -0.03 (7), the chiral center is shown in Figure 1; the crystal data is shown in Table 2, the data collection is shown in Table 3, the refinement parameters are shown in Table 4, and the results of other specific parameters are shown in Tables 5-7.

Table 2. Crystal data

C13H18BN5O3	$F(000) = 640$
$M_r = 303.13$	$D_x = 1.363 \text{ Mg m}^{-3}$
Monoclinic, C2	Cu Ka radiation, $\lambda = 1.54184 \text{ \AA}$
$a = 19.8507 (5) \text{ \AA}$	Cell parameters from 5850 reflections
$b = 6.6953 (2) \text{ \AA}$	$\Theta = 4.0\text{--}72.2^\circ$
$c = 12.3601 (3) \text{ \AA}$	$\mu = 0.81 \text{ mm}^{-1}$
$\beta = 115.925 (1)^\circ$	$T = 170 \text{ K}$
$V = 1477.42 (7) \text{ \AA}^3$	Block, colourless
$Z = 4$	$0.19 \times 0.12 \times 0.08 \text{ mm}$

Table 3. Data collection

D8 VENTURE diffractometer	$R_{\text{int}} = 0.027$
Absorption correction: multi-scan SADABS2016/2 (Bruker,2016/2) was used for absorption correction. $wR2(\text{int})$ was 0.1515 before and 0.0479 after correction. The Ratio of minimum to maximum transmission is 0.8576. The 1/2 correction factor is Not present.	$\Theta_{\text{max}} = 72.2^\circ$, $\Theta_{\text{min}} = 4.0^\circ$
$T_{\text{min}} = 0.646$, $T_{\text{max}} = 0.754$	$h = -22 \rightarrow 24$
6738 measured reflections	$k = -8 \rightarrow 8$
2751 independent reflections	$l = -15 \rightarrow 15$
2709 reflections with $I > 2\sigma(I)$	

Table 4.

Refinement on F^2	Hydrogen site location: mixed
Least-squares matrix: full	H atoms treated by a mixture of independent and constrained refinement
$R[F^2 > 2\sigma(F^2)] = 0.029$	$w = 1/[\sigma^2(F_{\text{o}}^2) + (0.0481P)^2 + 0.2566P]$ where $P = (F_{\text{o}}^2 + 2F_{\text{c}}^2)/3$
$wR(F^2) = 0.077$	$(\Delta/\sigma)_{\text{max}} < 0.001$
$S = 1.04$	$\Delta_{\text{max}} = 0.16 \text{ e \AA}^{-3}$
2751 reflections	$\Delta_{\text{min}} = -0.17 \text{ e \AA}^{-3}$

(continued)

5	Refinement on F^2	Hydrogen site location: mixed
205 parameters	Absolute structure: Flack x determined using 1136 quotients $[(I+)-(I-)]/[(I+)+(I-)]$ (Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259).	
1 restraint	Absolute structure parameter: 0.03 (7)	

10

Table 5. Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (\AA^2)

		x	y	z	U_{iso}^*/U_{eq}
15	O2	0.64183 (7)	0.3466 (2)	0.90349 (10)	0.0284 (3)
O3	0.73919 (7)	0.53879 (18)	0.88836 (11)	0.0272 (3)	
O1	0.64514 (6)	0.3533 (2)	0.71733 (10)	0.0250 (3)	
20	N2	0.44700 (8)	0.4545 (2)	0.59248 (13)	0.0261 (3)
N1	0.75403 (8)	0.1845 (2)	0.88956 (13)	0.0257 (3)	
N3	0.50499 (9)	0.8426 (3)	0.63775 (16)	0.0343 (4)	
25	N5	0.25974 (10)	0.5638 (3)	0.44136 (17)	0.0421 (4)
N4	0.38641 (10)	0.9765 (3)	0.53837 (19)	0.0418 (4)	
H4A	0.34431	0.959052	0.54561	0.050*	
30	H4B	0.409931	1.082673	0.580823	0.050*
C9	0.52051 (9)	0.4867 (3)	0.65153 (14)	0.0247 (3)	
C10	0.54820 (10)	0.6817 (3)	0.67279 (16)	0.0302 (4)	
35	H10	0.600853	0.700135	0.714619	0.036*
C6	0.57060 (10)	0.3066 (3)	0.69661 (15)	0.0258 (4)	
H6	0.5550774	0.195661	0.636741	0.031*	
40	C11	0.40272 (10)	0.6161 (3)	0.55589 (15)	0.0263 (4)
C1	0.80696 (10)	0.4983 (3)	0.87991 (16)	0.0288 (4)	
H1A	0.846548	0.593573	0.92966	0.035*	
45	H1B	0.799391	0.509148	0.795464	0.035*
C7	0.57939 (10)	0.2340 (3)	0.82101 (16)	0.0298 (4)	
H7	0.593762	0.089638	0.829854	0.036*	
50	C2	0.82872 (10)	0.2853 (3)	0.92620 (17)	0.0301 (4)
H2	0.85831	0.284276	1.015667	0.036*	
C13	0.32331 (10)	0.5819 (3)	0.49092 (16)	0.0307 (4)	
C12	0.43054 (10)	0.8133 (3)	0.57820 (16)	0.0303 (4)	
55	C5	0.74743 (12)	0.0217 (3)	0.80192 (18)	0.0365 (4)
H5A	0.696253	0.017265	0.735234	0.044*	
H5B	0.759279	-0.110065	0.842316	0.044*	
C8	0.51302 (12)	0.2583 (4)	0.84878 (19)	0.0442 (5)	
H8A	0.524991	0.201813	0.928255	0.066*	
H8B	0.469703	0.188319	0.787783	0.066*	

(continued)

	<i>x</i>	<i>y</i>	<i>z</i>	<i>Uiso*/Ueq</i>	
5	H8C	0.501252	0.400526	0.848327	0.066*
	B1	0.69082 (11)	0.3664 (3)	0.84626 (16)	0.0242 (4)
	C3	0.86852 (13)	0.1659 (4)	0.8665 (2)	0.0454 (5)
	H3A	0.900125	0.059633	0.920509	0.054*
	H3B	0.900172	0.253516	0.843131	0.054*
	C4	0.80418 (16)	0.0773 (4)	0.7561 (2)	0.0474 (6)
	H4C	0.783299	0.176608	0.690291	0.057*
	H4D	0.82071	-0.041813	0.726658	0.057*
10	H1	0.7538 (12)	0.131 (3)	0.954 (2)	0.019 (5)
15					

Table 6. Atomic displacement parameters

	<i>U11</i>	<i>U22</i>	<i>U33</i>	<i>U12</i>	<i>U13</i>	<i>U23</i>	
20	O2	0.0275 (6)	0.0368 (7)	0.0209 (6)	0.0011 (5)	0.0104 (5)	-0.0008 (5)
	O3	0.0266 (6)	0.0268 (6)	0.0262 (6)	0.0009 (5)	0.0098 (5)	-0.0030 (5)
	O1	0.0217 (5)	0.0321 (6)	0.0200 (5)	0.0001 (5)	0.0079 (4)	0.0013 (5)
	N2	0.0241 (7)	0.0331 (8)	0.0208 (6)	-0.0024 (6)	0.0094 (5)	0.0003 (6)
	N1	0.0295 (7)	0.0266 (7)	0.0208 (7)	0.0026 (6)	0.0109 (5)	0.0016 (6)
	N3	0.0259 (7)	0.0318 (8)	0.0422 (9)	-0.0017 (7)	0.0122 (6)	-0.0002 (7)
	N5	0.0254 (8)	0.0602 (12)	0.0388 (9)	-0.0039 (8)	0.0122 (7)	-0.0088 (8)
	N4	0.0276 (8)	0.0350 (9)	0.0615 (11)	0.0030 (7)	0.0181 (8)	0.0029 (9)
25	C9	0.0226 (8)	0.0319 (9)	0.0189 (7)	-0.0019 (7)	0.0083 (6)	0.0003 (7)
	C10	0.0221 (8)	0.0333 (9)	0.0318 (9)	-0.0025 (7)	0.0087 (7)	-0.0027 (8)
	C6	0.0241 (8)	0.0296 (9)	0.0224 (7)	-0.0022 (7)	0.0089 (6)	-0.0013 (6)
	C11	0.0213 (8)	0.0341 (9)	0.0235 (8)	-0.0010 (6)	0.0097 (6)	-0.0002 (7)
	C1	0.0275 (8)	0.0332 (9)	0.0267 (8)	-0.0015 (7)	0.0127 (7)	-0.0029 (7)
	C7	0.0282 (8)	0.0353 (9)	0.0251 (8)	-0.0007 (7)	0.0111 (7)	0.0031 (7)
	C2	0.0256 (8)	0.0378 (10)	0.0260 (8)	0.0033 (7)	0.0103 (7)	0.0017 (7)
	C13	0.0263 (9)	0.0393 (9)	0.0271 (8)	-0.0008 (7)	0.0123 (7)	-0.0026 (8)
30	C12	0.0254 (8)	0.0347 (10)	0.0319 (9)	0.0001 (7)	0.0134 (7)	0.0004 (7)
	C5	0.0476 (11)	0.0272 (9)	0.0324 (9)	0.0068 (8)	0.0152 (9)	-0.0026 (8)
	C8	0.0336 (10)	0.0711 (15)	0.0318 (9)	-0.0015 (10)	0.0180 (8)	0.0100 (10)
	B1	0.0260 (8)	0.0251 (9)	0.0199 (8)	0.0038 (7)	0.0086 (7)	0.0012 (7)
	C3	0.0426 (11)	0.0460 (12)	0.0595 (13)	0.0105 (10)	0.0333 (10)	0.0038 (11)
	C4	0.0762 (16)	0.0385 (11)	0.0413 (11)	0.0140 (11)	0.0385 (12)	0.0026 (10)
35							
40							
45							
50							

Table 7. Geometric parameters (Å, °)

O2-C7	1.428 (2)	C6-C7	1.548 (2)
-------	-----------	-------	-----------

(continued)

5	O2-B1	1.437(2)	C11-C13	1.441 (2)
10	O3-C1	1.420 (2)	C11-C12	1.411 (3)
15	O3-B1	1.445 (2)	C1-H1A	0.99
20	O1-C6	1.422 (2)	C1-H1B	0.99
25	O1-B1	1.451 (2)	C1-C2	1.527 (3)
30	N2-C9	1.333 (2)	C7-H7	1
35	N2-C11	1.342 (2)	C7-C8	1.508 (3)
40	N1-C2	1.507 (2)	C2-H2	1
45	N1-C5	1.502 (2)	C2-C3	1.523 (3)
50	N1-B1	1.660 (2)	C5-H5A	0.99
55	N1-H1	0.88 (2)	C5-H5B	0.99
	N3-C10	1.327 (3)	C5-C4	1.513 (3)
	N3-C12	1.346 (2)	C8-H8A	0.9800
	N5-C13	1.143 (3)	C8-H8B	0.9800
	N4-H4A	0.8861	C8-H8C	0.9800
	N4-H4B	0.8860	C3-H3A	0.9900
	N4-C12	1.351 (3)	C3-H3B	0.9900
	C9-C10	1.396 (3)	C3-C4	1.524 (4)
	C9-C6	1.506 (2)	C4-H4C	0.9900
	C10-H10	0.9500	C4-H4D	0.9900
	C6-H6	1.0000		
35	C7-O2-B1	105.08 (13)	N1-C2-C1	103.04 (13)
	C1-O3-B1	108.83 (14)	N1-C2-H2	110.7
	C6--O1-B1	108.20 (13)	N1-C2-C3	105.66 (17)
40	C9-N2-C11	116.93 (16)	C1-C2-H2	110.7
	C2-N1-B1	105.90 (14)	C3-C2-C1	115.48 (17)
	C2-N1-H1	107.7 (14)	C3-C2-H2	110.7
	C5-N1-C2	107.82 (15)	N5-C13-C11	176.6 (2)
45	C5-N1-B1	118.98 (13)	N3-C12-N4	117.58 (18)
	C5-N1-H1	109.2 (14)	N3-C12-C11	119.05 (17)
	B1-N1-H1	106.7 (14)	N4-C12-C11	123.31 (16)
50	C10-N3-C12	117.29 (17)	N1-C5-H5A	110.9
	H4A-N4-H4B	108.8	N1-C5-H5B	110.9
	C12-N4-H4A	110.3	N1-C5-C4	104.31 (17)
	C12-N4-H4B	110.1	H5A-C5-H5B	108.9
55	N2-C9-C10	120.07 (17)	C4-C5-H5A	110.9
	N2-C9-C6	117.42 (16)	C4-C5-H5B	110.9
	C10-C9-C6	122.48 (15)	C7-C8-H8A	109.5

(continued)

5	N3-C10-C9	123.57 (16)	C7-C8-H8B	109.5
	N3-C10-H10	118.2	C7-C8-H8C	109.5
	C9-C10-H10	118.2	H8A-C8-H8B	109.5
10	O1-C6-C9	110.96 (14)	H8A-C8-H8C	109.5
	O1-C6-H6	109.8	H8B-C8-H8C	109.5
	O1-C6-C7	103.51 (13)	O2-B1-O3	112.50 (14)
	C9-C6-H6	109.8	O2-B1-O1	107.61 (14)
15	C9-C6-C7	112.86 (15)	O2-B1-N1	110.64 (14)
	C7-C6-H6	109.8	O3-B1-O1	116.20 (15)
	N2-C11-C13	117.11 (17)	O3-B1-N1	100.38 (13)
20	N2-C11-C12	123.09 (15)	O1-B1-N1	109.33 (14)
	C12-C11-C13	119.80 (17)	C2-C3-H3A	111.1
	O3-C1-H1A	110.6	C2-C3-H3B	111.1
	O3-C1-H1B	110.6	C2-C3-C4	103.25 (17)
25	O3-C1-C2	105.82 (14)	H3A-C3-H3B	109.1
	H1A-C1-H1B	108.7	C4-C3-H3A	111.1
	C2-C1-H1A	110.6	C4-C3-H3B	111.1
30	C2-C1-H1B	110.6	C5-C4-C3	103.32 (17)
	O2-C7-C6	103.23 (14)	C5-C4-H4C	111.1
	O2-C7-H7	108.4	C5-C4-H4D	111.1
35	O2-C7-C8	110.64 (16)	C3-C4-H4C	111.1
	C6-C7-H7	108.4	C3-C4-H4D	111.1
	C8-C7-C6	117.49 (16)	H4C-C4-H4D	109.1
	C8-C7-H7	108.4		


40 [0251] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the various technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combinations of these technical features, all of the combinations should be considered within the scope of this specification.

45 [0252] The above-mentioned embodiments only express several embodiments of the present invention, and the descriptions are more specific and detailed, but they should not be understood as limitations to the scope of the patent of the present invention. It should be pointed out that for ordinary technician in the field, under the premise of not deviating from the idea of the invention, several modifications and improvements can be made, and these all fall within the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention should be subject to the appended claims.


50 **Claims**

1. Intermediate with structure as shown in formula (IVa-1), formula (IVa-2), formula (IVa-3), formula (IVa-4), formula (IVa) or formula (IVa'):

5




10



15

In which,

20



25

represents the structure generated by the reaction of dihydroxyl, the first reagent and the second reagent;

30

represents the structure generated by the reaction of dihydroxyl and the first reagent;

The first reagent is boric acid ester or boric acid;

The second reagent is chiral amino alcohol;

W is NH_x , and X is 0, 1 or 2;

R_1 is a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

35

R_2 and R_3 are independently a hydrogen atom or an amino protecting group; and R_2 and R_3 together with the nitrogen atom connected to R_2 and R_3 can form a cyclic lactim group;

R_4 is $-\text{COOR}_5$, $-\text{CONR}_6$ or $-\text{CN}$;

R_5 and R_6 are independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;

40


Z is a hydrogen atom or a leaving group;

Y is O or absent.


45

2. The intermediate according to claim 1, **characterized in that** Y is absent, Z is a hydrogen atom, R_4 is a cyano, and R_1 is a methyl.
3. The intermediate according to claim 1, **characterized in that** the first reagent is a boric acid ester; the second reagent is a chiral amino alcohol.
- 50 4. The intermediate according to claim 3, **characterized in that** R_8 is substituted or unsubstituted C_{1-10} alkyl, substituted or unsubstituted C_{3-10} cycloalkyl; and/or

55



has the following structure:



10 In which at least one of the carbon atom connected to R₂₀ and R₂₁ and the carbon atom connected to R₂₂ and R₂₃ is a chiral carbon;

15 R₂₀, R₂₁, R₂₂ and R₂₃ are independently selected from: H, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, or substituted or unsubstituted quinolyl;

20 R₂₄ and R₂₅ are independently selected from: H, substituted or unsubstituted C₁₋₆ alkyl, or substituted or unsubstituted phenyl;

25 R₂₃ and R₂₄ can connect with each other to form a ring structure;


R₂₃, R₂₄ and R₂₅ can connect with each other to form a bridged ring structure.

5. The intermediate according to claim 4, **characterized in that** R₂₀, R₂₁, R₂₂, and R₂₃ are independently selected from H, phenyl, C₁₋₆ alkyl, or C₁₋₆ alkoxy substituted quinoliny;

20 R₂₄ and R₂₅ are independently selected from: H, C₁₋₆ alkyl or phenyl;

25 R₂₃ and R₂₄ can be interconnected to form a five-membered nitrogen heterocycle;

R₂₃, R₂₄ and R₂₅ can be interconnected to form




30 structure.

6. The intermediate according to claim 1, **characterized in that** the boric acid ester is selected from: trimethyl borate, triethyl borate, triisopropyl borate or isopropoxyboronic acid pinacol ester;

35 The chiral amino alcohol is selected from: L-phenylglycinol, L-prolinol, L-phenylalaninol, (S)-(-)- α,α -diphenylprolinol, quinine or cinchoni.

7. The preparation method of intermediate according to any one of claims 1-6, is **characterized in that** it includes the following steps:

40 Mix the compound to be separated, the first reagent, the second reagent and the aprotic solvent, and heat to reflux for reaction. After the reaction is completed, crystallize to obtain the intermediate with the structure as shown in formula (IVa-1) or formula (IVa-2); among them, the compound to be separated is a mixture of the compounds represented by formula (IVa) and formula (IVa');



Formula (IVa)

Formula (IVa').

50 8. The preparation method according to claim 7, **characterized in that** the compound to be separated reacts with the first reagent to generate a mixture of the structures shown in formula (IVa-3) and (IVa-4); the mixture of the structures shown in formula (IVa-3) and (IVa-4) reacts with the second reagent to generate the intermediate of the structure shown in formula (IVa-1) or (IVa-2).

55 9. The preparation method according to claim 7, **characterized in that** the aprotic solvent is selected from one or more of the following reagents: tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, acetonitrile, toluene, benzene, xylenes, 1,4-dioxane, acetone and MIBK; and/or

The molar ratio of the compound to be separated and the second reagent is less than or equal to 1; and/or
 The molar ratio of the first reagent and the second reagent is 1:(1.0-1.3); and/or
 add 1 mL-100 mL of the aprotic solvent into 1 g of the compound to be separated.

5 10. Application of the intermediate according to any one of claims 1-6 in the preparation of L-erythro biopterin compound.

10 11. A method for preparing L-erythro biopterin compound, **characterized in that** the L-erythro biopterin compound have
 the structure shown in formula (I), and the L-erythro biopterin compound represented by formula (I) are prepared
 by dihydroxylation of the compound represented by formula (II) or the compound represented by formula (III);

10

15

20

25

In which,

Y is O or absent;
 Z is a hydrogen atom or a leaving group;
 30 R_1 is a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
 R_2 and R_3 are independently a hydrogen atom or an amino protecting group; and R_2 and R_3 together with the nitrogen atom connected to R_2 and R_3 can form a cyclic lactim group;
 R_4 is $-COOR_5$, $-CONR_6$ or $-CN$;
 35 R_5 and R_6 are independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
 R_7 is $-OH$ or $-NH_2$.

40 12. The method for preparing L-erythro biopterin compound according to claim 11, **characterized in that** R_5 and R_6 are independently selected from: hydrogen atom, or substituted or unsubstituted C_{1-20} alkyl;
 The R_1 is selected from: C_{1-6} alkyl, 3-8 membered cycloalkyl, 3-10 membered aryl, 3-10 membered heteroaryl, TMS, TBS, or $-CH_2X$; X is a leaving group.

45 13. The method for preparing L-erythro biopterin compound according to claim 12, **characterized in that** the leaving group is selected from: silicil group, halogen, OSO_nR_9 , $OCOR_{10}$ or OPO_2R_{11} ; in which R_9 , R_{10} or R_{11} is independently selected from: $-CF_3$, alkyl, phenyl, or alkyl substituted phenyl, n is 0, 1 or 2; and/or
 The amino protecting group is selected from: -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or schiff base.

50 14. The method for preparing L-erythro biopterin compound according to claim 13, **characterized in that** Y is absent, Z is a hydrogen atom, R_4 is a cyano, and R_1 is a methyl.

55 15. The method for preparing L-erythro biopterin compound according to claim 11, **characterized in that** when the alkene in the compound represented by formula (II) is of a cis structure and its structural formula is represented by formula (IIa), the steps for preparing L-erythro biopterin compound represented by formula (I) from the compound represented by formula (IIa) are as follows:

The compound represented by formula (IIa) undergoes a dihydroxylation reaction to obtain the compound to

be separated which is composed of the compounds represented by formula (IVa) and formula (IVa');
 The compound to be separated is separated by chiral separation reagent set to obtain the compound represented by formula (IVa-1);
 The compound represented by formula (IVa-1) undergoes a cyclization reaction with

5



10

and/or the salt of


15



20

followed by a hydrolysis reaction to obtain the L-erythro biopterin compound represented by formula (I);
 Among them, the chiral separation reagent set includes the first reagent and the second reagent. The first reagent is boric acid ester or boric acid;
 The second reagent is chiral amino alcohol;


25



, W, Z, Y, R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in claim 1;
 E is halogen, C₁₋₄ alkoxy, C₁₋₄ alkyl sulphanyl or -NH₂;

30

35



40

16. The method for preparing L-erythro biopterin compound according to claim 15, **characterized in that** after the steps for obtaining the compound represented by formula (IVa-1), there are also the following steps:

45

Mix the compound represented by formula (IVa-1) with protonic solvent to obtain the compound represented by formula (IVa);

The compound represented by formula (IVa) undergoes a cyclization reaction with

50




and/or the salt of

55



followed by a hydrolysis reaction to obtain the L-erythro biopterin compound represented by formula (I);



10 17. The method for preparing L-erythro biopterin compound according to claim 15, **characterized in that** the steps of a cyclization reaction of the compound represented by formula (IVa-1) with



and/or the salt of




followed by a hydrolysis reaction are as follows: Mix the compound represented by formula (IVa-1),



and/or the salt of



35 , base and protonic solvent, and heat to 50-100°C for reaction. After the reaction is completed, cool. A solid substance is precipitated. Filter to obtain the compound represented by formula (I-1);
Add the compound represented by formula (I-1) into an alkaline solution. After the reaction is completed, add acid, and adjust the pH to 5-6. Crystals are precipitated. Filter and dry to obtain the L-erythro biopterin compound represented by formula (I);



R₇ is -OH or -NH₂.

50 18. The method for preparing L-erythro biopterin compound according to claim 15, **characterized in that** the boric acid ester is selected from: trimethyl borate, triethyl borate, triisopropyl borate or isopropoxyboronic acid pinacol ester; The chiral amino alcohol is selected from: L-phenylglycinol, L-prolinol, L-phenylalaninol, (S)-(-)-α,α-diphenylprolinol, quinine or cinchoni.

55 19. The method for preparing L-erythro biopterin compound according to claim 11, **characterized in that** when the alkene in the compound represented by formula (II) is of a trans structure and its structural formula is represented by formula (IIb), the steps for preparing the L-erythro biopterin compound represented by formula (I) from the

compound represented by formula (IIb) are as follows:

The compound represented by the formula (IIb) is subjected to a dihydroxylation reaction to prepare the compound represented by the formula (IVb-1) and/or formula (IVb-2);

The compound represented by formula (IVb-1) and/or formula (IVb-2) undergoes an acetylation reaction to obtain the compound represented by formula (VIIb-1) and/or formula (VIIb-2);

The compound represented by formula (VIIb-1) and/or formula (VIIb-2) undergoes the Mitsunobu reaction to obtain the compound represented by formula (VIIb-3) and/or formula (VIIb-4);

The compound represented by (VIIb-3) and/or formula (VIIb-4) undergoes a cyclization reaction with

10



15


and/or the salt of



20

to obtain the L-erythro biopterin compound represented by formula (I);

25




30

35

40

45

50



In which R_{10} is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; E is halogen, C_{1-4} alkoxy, C_{1-4} alkylthio or $-NH_2$.

55 20. The method for preparing L-erythro biopterin compound according to any one of claims 11-19, characterized in that the dihydroxylation reaction method is Sharpless asymmetric dihydroxylation reaction, basic $KMnO_4$ dihydroxylation reaction, Fe-catalyzed dihydroxylation or asymmetric epoxidation followed by hydrolysis and ring opening.

21. The method for preparing L-erythro biopterin compound according to claim 20, characterized in that the compound represented by formula (IIa) and/or formula (IIb) undergoes a dihydroxylation reaction by the Sharpless asymmetric dihydroxylation reaction. The steps of the Sharpless asymmetric dihydroxylation reaction are as follows:

Mix the compound represented by formula (IIa) and/or the compound represented by formula (IIb), oxidizing agent, dihydroxylation reagent, base, ligand, and solvent for reaction. After the reaction is completed, quench the reaction, and separate;


Among them, the dihydroxylation reagent is selected from one or more of the following reagents: OSO_4 , K_2OsO_4 , OsO_4 hydrate and K_2OsO_4 hydrate;

The oxidant is selected from one or more of the following reagents: $K_3[Fe(CN)_6]$ or NMO;


The base is selected from one or more of potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, NaOH, KOH, LiOH, NH₄OH, t-BuONa, t-BuOK, t-BuOLi, cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine and p-dimethylaminopyridine;

The ligand is selected from one or more of the following reagents: $(DHQ)_2PHAL$, $(DHQD)_2PHAL$, DHQ-IND and DHQD-IND.

22. The method for preparing L-erythro biopterin compound according to claim 11, **characterized in that**, When the alkene in the compound represented by formula (II) is of a cis structure and its structural formula is represented by formula (IIa), the compound represented by formula (IIa) is obtained by a catalytic hydrogenation reaction of the compound represented by formula (V):



When the alkene in the compound represented by the formula (II) is of a trans structure and its structural formula is represented by formula (IIb), the compound represented by formula (IIb) is obtained by a coupling reaction of the compound represented by formula (VI);



In which M is H or a leaving group.

23. The method for preparing L-erythro biopterin compound according to claim 22, characterized in that the steps of the catalytic hydrogenation reaction are as follows:

Mix the compound represented by formula (V), catalyst and solvent, and react under hydrogen atmosphere.

After the reaction is completed, filter and concentrate to obtain the compound represented by formula (IIa);

The catalyst is selected from one or more of nickel, platinum black and platinum dioxide;

The solvent is selected from one or more of the following reagents: tetrahydrofuran, 2-methyltetrahydrofuran, ethyl ether, methyl tert-butyl ether, methyl cyclopentyl ether, methanol, ethanol, isopropanol, acetonitrile and toluene.

24. The method for preparing L-erythro biopterin compound according to claim 22, characterized in that the steps of the coupling reaction are as follows:

Mix the compound represented by formula (VI), trans-1-propenyl boronic acid reagent, catalyst, solvent and ligand for reaction. After the reaction is completed, separate to obtain the compound represented by formula (IIIb) ;


The trans-1-propenyl boronic acid reagent is selected from: trans-1-propenyl boronic acid pinacol ester, trans-1-propenyl boronic acid or trans-1-propenyl fluoroborinate;

The catalyst is selected from one or more of the following reagents: 5%Pd/C, 10%Pd/C, $\text{Pd}(\text{OAc})_2$, $\text{PdCl}_2(\text{PPh}_3)_2$, $\text{Pd}(\text{PPh}_3)_4$, $\text{PdCl}_2(\text{dpdpf})$, $\text{PdCl}_2(\text{MeCN})_2$ and $\text{Pd}_2(\text{dba})_3$;

The solvent is selected from one or more of the following reagents: methanol, ethanol, isopropanol, butanol, water, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, DME, DMF, DMSO, NMP, acetonitrile, dichloromethane, 1,2-dichloroethane, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, ethyl ether, methyl tert-butyl ether, toluene, xylene, acetone, methyl ethyl ketone and methyl cyclopentane;

The ligands are selected from one or more of the following reagents: PPh_3 , BINAP, dppf, Xantphos, Xphos monophosphorus and diphosphorus ligands.

25. The method for preparing L-erythro biopterin compound according to claim 22, characterized in that the compound represented by formula (V) is obtained by the Sonogashira reaction of the compound represented by formula (VI);



26. The method for preparing L-erythro biopterin compound according to claim 25, characterized in that the steps of the Sonogashira reaction are as follows:

Mix the compound represented by formula (VI), catalyst, ligand and solvent; add the base and





for reaction. After the reaction is completed, quench the reaction, and separate to obtain the compound represented by formula (V).

27. The method for preparing L-erythro biopterin compound according to claim 11, characterized in that the compound represented by formula (III) is obtained by a cyclization reaction of the compound represented by formula (II) with



and/or the salt of




E is halogen, C₁₋₄ alkoxy, C₁₋₄ alkylthio or -NH₂.

28. The method for preparing L-erythro biopterin compound according to claim 11, characterized in that, When the alkene in the compound represented by the formula (III) is of a cis structure and its structural formula is represented by formula (IIIa), the compound represented by formula (IIIa) is obtained by a catalytic hydrogenation reaction of

the compound represented by formula (VIII):

5




10 29. The method for preparing L-erythro biopterin compound according to claim 28, **characterized in that** the compound represented by formula (VIII) is prepared by the following steps:

The compound represented by formula (VI) undergoes the Sonogashira reaction to obtain the compound represented by formula (V);

15

The compound represented by formula (V) undergoes cyclization to obtain the compound represented by formula (VIII);

20



In which M is H or a leaving group.

25

30


35

40

45

50

55



PLAT791 ALERT 4 G Model has Chirality at N1
And 3 other PLAT791 Alerts

(Chiral SPCR)

S Verify

PLAT791 ALERT 4 G Model has Chirality at C2
PLAT791 ALERT 4 G Model has Chirality at C6
PLAT791 ALERT 4 G Model has Chirality at C7

(Chiral SPCR)

S Verify

(Chiral SPCR)

R Verify

(Chiral SPCR)

S Verify

Fig 1

INTERNATIONAL SEARCH REPORT		International application No. PCT/CN2020/109818															
5	A. CLASSIFICATION OF SUBJECT MATTER C07F 5/02(2006.01)i; C07D 241/02(2006.01)i According to International Patent Classification (IPC) or to both national classification and IPC																
10	B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07F; C07D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																
15	Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CNKI, CNABS, Sipoabs, DWPI, VEN, REGISTRY, CASREACT, CAPLUS, MARPAT: 赤型生物蝶呤, 沙丙蝶呤, 制备, 合成, 中间体, intermediate, prepare, synthesize, erythro, biopterin, pterin, Sapropterin, sub-structure or reaction formula search according to claim 1.																
20	C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category*</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: left; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; padding: 2px;">X</td> <td style="padding: 2px;">Taylor, Edward C. et al. "Pteridines. XXXVII. A total synthesis of L-erythro-bioppterin and some related 6-(polyhydroxyalkyl)pterins" <i>Journal of the American Chemical Society</i>, Vol. 98, No. 8, 31 December 1976 (1976-12-31), pages 2301-2307, see page 2302, scheme III</td> <td style="text-align: center; padding: 2px;">1-6, 10</td> </tr> <tr> <td style="text-align: center; padding: 2px;">X</td> <td style="padding: 2px;">Taylor, Edward C. et al. "Pteridines. XXXIII. Unequivocal total synthesis of L-erythro-Bioppterin" <i>Journal of the American Chemical Society</i>, Vol. 96, No. 21, 31 December 1974 (1974-12-31), pages 6781-6782, see scheme I-III</td> <td style="text-align: center; padding: 2px;">1-6, 10</td> </tr> <tr> <td style="text-align: center; padding: 2px;">A</td> <td style="padding: 2px;">Taylor, Edward C. et al. "Pteridines. XXXVII. A total synthesis of L-erythro-bioppterin and some related 6-(polyhydroxyalkyl)pterins" <i>Journal of the American Chemical Society</i>, Vol. 98, No. 8, 31 December 1976 (1976-12-31), pages 2301-2307, see page 2302, scheme III</td> <td style="text-align: center; padding: 2px;">7-9, 11-29</td> </tr> <tr> <td style="text-align: center; padding: 2px;">A</td> <td style="padding: 2px;">Taylor, Edward C. et al. "Pteridines. XXXIII. Unequivocal total synthesis of L-erythro-Bioppterin" <i>Journal of the American Chemical Society</i>, Vol. 96, No. 21, 31 December 1974 (1974-12-31), pages 6781-6782, see scheme I-III</td> <td style="text-align: center; padding: 2px;">7-9, 11-29</td> </tr> </tbody> </table>		Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	Taylor, Edward C. et al. "Pteridines. XXXVII. A total synthesis of L-erythro-bioppterin and some related 6-(polyhydroxyalkyl)pterins" <i>Journal of the American Chemical Society</i> , Vol. 98, No. 8, 31 December 1976 (1976-12-31), pages 2301-2307, see page 2302, scheme III	1-6, 10	X	Taylor, Edward C. et al. "Pteridines. XXXIII. Unequivocal total synthesis of L-erythro-Bioppterin" <i>Journal of the American Chemical Society</i> , Vol. 96, No. 21, 31 December 1974 (1974-12-31), pages 6781-6782, see scheme I-III	1-6, 10	A	Taylor, Edward C. et al. "Pteridines. XXXVII. A total synthesis of L-erythro-bioppterin and some related 6-(polyhydroxyalkyl)pterins" <i>Journal of the American Chemical Society</i> , Vol. 98, No. 8, 31 December 1976 (1976-12-31), pages 2301-2307, see page 2302, scheme III	7-9, 11-29	A	Taylor, Edward C. et al. "Pteridines. XXXIII. Unequivocal total synthesis of L-erythro-Bioppterin" <i>Journal of the American Chemical Society</i> , Vol. 96, No. 21, 31 December 1974 (1974-12-31), pages 6781-6782, see scheme I-III	7-9, 11-29
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
X	Taylor, Edward C. et al. "Pteridines. XXXVII. A total synthesis of L-erythro-bioppterin and some related 6-(polyhydroxyalkyl)pterins" <i>Journal of the American Chemical Society</i> , Vol. 98, No. 8, 31 December 1976 (1976-12-31), pages 2301-2307, see page 2302, scheme III	1-6, 10															
X	Taylor, Edward C. et al. "Pteridines. XXXIII. Unequivocal total synthesis of L-erythro-Bioppterin" <i>Journal of the American Chemical Society</i> , Vol. 96, No. 21, 31 December 1974 (1974-12-31), pages 6781-6782, see scheme I-III	1-6, 10															
A	Taylor, Edward C. et al. "Pteridines. XXXVII. A total synthesis of L-erythro-bioppterin and some related 6-(polyhydroxyalkyl)pterins" <i>Journal of the American Chemical Society</i> , Vol. 98, No. 8, 31 December 1976 (1976-12-31), pages 2301-2307, see page 2302, scheme III	7-9, 11-29															
A	Taylor, Edward C. et al. "Pteridines. XXXIII. Unequivocal total synthesis of L-erythro-Bioppterin" <i>Journal of the American Chemical Society</i> , Vol. 96, No. 21, 31 December 1974 (1974-12-31), pages 6781-6782, see scheme I-III	7-9, 11-29															
30	<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																
35	<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>																
40	Date of the actual completion of the international search 13 October 2020																
45	Date of mailing of the international search report 28 October 2020																
50	Name and mailing address of the ISA/CN China National Intellectual Property Administration (ISA/CN) No. 6, Xitucheng Road, Jimenqiao Haidian District, Beijing 100088 China																
55	Facsimile No. (86-10)62019451																

INTERNATIONAL SEARCH REPORT		International application No. PCT/CN2020/109818	
5	C. DOCUMENTS CONSIDERED TO BE RELEVANT		
	Category*	Citation of document, with indication, where appropriate, of the relevant passages	
10	A	DeGraw, Joseph I. et al. "Synthesis of biopterin-8a-13C" <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , Vol. 16, No. 4, 31 December 1979 (1979-12-31), pp. 559-565	1-29
15	A	Zhang, Fang-Li et al. "A new synthesis of ciliapterin and dictyopterin. Ene reactions of (alkenylamino)-nitroso-pyrimidines" <i>Helvetica Chimica Acta</i> , Vol. 91, No. 12, 31 December 2008 (2008-12-31), pp. 2351-2360	1-29
20	A	Schircks, Bernhard et al. "Pterine chemistry. 84. A new, regiospecific synthesis of L-biopterin" <i>Helvetica Chimica Acta</i> , Vol. 68, No. 6, 31 December 1985 (1985-12-31), pp. 1639-1643	1-29
25	A	Jacobi, Peter A. et al. "Unequivocal synthesis of euglenapterin" <i>Journal of Organic Chemistry</i> , Vol. 46, No. 26, 31 December 1981 (1981-12-31), pages 5416-5418, see scheme I-III	1-29
30			
35			
40			
45			
50			
55			

Form PCT/ISA/210 (second sheet) (January 2015)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- CN 2019107645414 [0001]
- CN 2020108063470 [0001]
- US 3505329 A, Welustock J. [0007]

Non-patent literature cited in the description

- ANDREWS et al. *J. Chem. Soc.*, 1969, 928 [0006]
- TAYLOR E.C. *J. Am. Chem. Soc.*, 1979, vol. 98, 2301 [0007]
- *Helv chim acta*, vol. 1985, 1639 [0007]
- *Journal of Organic Chemistry*, 1987, vol. 52 (18), 3997-4000 [0089]
- *Journal of Organic Chemistry*, 1988, vol. 53(1), 35-38 [0089]
- *J.J. Chem. Soc., Chem. Commun.*, 1983, vol. 15, 793-794 [0142]
- *Chemistry Letters*, 2014, vol. 43 (6), 922-924 [0142]
- *Chemistry-An Asian Journal*, 2012, vol. 7 (5), 1061-1068 [0142]
- *J.Org.Chem.*, 1990, vol. 55, 3019 [0142]
- *J. Chem. Soc., Chem. Commun.*, 1977, 683-684 [0142]